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Abstract
Sepsis is a systemic inflammatory response that results the presence and persistence of microorganisms or
their toxins in the bloodstream and it is diagnosed by detecting the presence of pathogens in blood.
Despite improvements in modem medicine, sepsis has a high mortality rate that increases rapidly with
every hour the patient does not receive optimal antibiotic therapy. Thus, there is a great demand for
technologies that can accelerate pathogen detection and sepsis diagnosis. Our lab previously developed a
micromagnetic-microfluidic pathogen isolation technology that can selectively remove pathogens from
flowing whole human blood with high efficiency using micro- or nano-sized magnetic beads coated with
microbe-specific antibodies [1, 2]. However, the identity of the pathogen is not known when a patient
first presents with the clinical symptoms of sepsis, and currently, it can take days to a week to identify the
specific pathogen type. The goal of this dissertation is to develop a generic pathogen collection
technology that can be used to pull bacteria and fungi out of blood or other fluids without first knowing
their identity, and to concentrate them for analysis and rapid identification. In Chapter 1, 1 will review the
field of sepsis diagnostics and methods that have been employed to confront this challenge. In Chapter 2,
I describe the development of a natural human opsonin - Mannose Binding Lectin (MBL) - as a generic
pathogen capture molecule. MBL is found in human blood and is part of the innate immune system; it has
been previously shown to bind over 90 different types of pathogens, including gram negative and positive
bacteria, fungi, viruses and parasites [3-5]. The studies described in this chapter include development and
optimization of methods to coat magnetic beads with MBL and demonstration that MBL beads bind to
wide range of pathogens with high efficiency in saline and blood. The binding of MBL beads to sample
pathogens is tested under a wide range of conditions to determine optimal bead concentration, binding
time and sample treatments to maximize binding in blood. In Chapter 3, 1 describe development of a
device that efficiently concentrates and visualizes fungi tagged with the magnetic MBL micro beads.
Visualization is made possible by controlling the balance of fluidic shear stress and magnetic force on the
tagged pathogens in the device, which enables spreading of the beads and bound fungi into a uniform
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layer that can be quickly quantified with fluorescent microscopy. Chapter 4 describes tools that I have
developed to rapidly concentrate and purify magnetically tagged bacteria from blood and other complex
samples for polymerase chain reaction (PCR) detection. The MBL-bead approach is used to pull out and
concentrate pathogens from large sample volumes, and to remove contaminating human DNA, so that
sensitive detection can be carried out using PCR amplification. The efficiency of this new MBL-based,
sample pre-concentration method is compared to existing commercial isolation methods for analysis of
both blood and food samples. Finally, I discuss the implications of these findings in Chapter 5.
Thesis Supervisor: Donald E. Ingber
Title: Professor of Vascular Biology & Bioengineering
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Glossary
P2d Density of bead packing on two dimensional surfaces
p Magnetic Dipole
19 Fluid viscosity
AST Antibiotic Susceptibility Testing
B Magnetic Field
Cb Concentration of magnetic beads
cc Concentration of target pathogens
Cq Threshold cycle for sample in qPCR amplification
D Diffusivity
Dc Diffusivity of target pathogens
Db Diffusivity of magnetic beads
EDTA Ethylenediaminetetraacetic acid, a common anticoagulant that chelates calcium
Fm Magnetic force on the beads induced by the magnetic field
Fd Drag force on beads and/or pathogens
IgG Immunoglobulin G
FcMBL Recombinant version of FcMBL
MRSA Methicillin Resistant Staphylococcus aureus
MBL Mannose Binding Lectin
N Number of beads of attached to the pathogens
PCR Polymerase Chain Reaction
PDMS polydimethylsiloxane (PDMS), also called Sylgard 184 (Dow Corning)
Pe Peclet number
qPCR Quantitative Polymerase Chain Reaction
Reb Collision rate between magnetic bead and pathogen
rc Radius of target pathogen
rb Radius of target bead
SU-8 Negative photoresist used to make molds for soft lithography
t time
T Absolute temperature
TBS Tris Buffered Saline
veb Relative velocity of bead and pathogen relative to each other
vdiff Diffusion velocity of the beads towards the pathogen
vs Settling velocity of magnetic bead toward the ceiling of the microchannel
VRE Vancomycin-Resistant Enterococcus
WtMBL Wild type mannose binding lectin
u Representative velocity
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Chapter 1 Introduction
1.1 What is Sepsis
The Center for Disease Control defines sepsis as a systemic disease associated with the
presence and persistence of pathogenic microorganisms or their toxins in the bloodstream [6].
The infection itself is usually caused by a single species that manages to escape eradication by
the immune system and begins to spread throughout the entire body, causing widespread release
of cytokines that begins the immune dysregulation which drives the downward spiral [7]. As a
disease, sepsis progresses through several stages (Figure 1.1). The first stage is systemic
inflammatory response syndrome (SIRS), characterized by abnormal temperature, tachycardia,
tachypnea and abnormal white blood cell counts, all caused by large scale dysregulation of
inflammatory cytokines, commonly known as a 'cytokine storm.' In addition to live bacteria,
fragments of bacteria such as peptidoglycan, lipoteichoic acid, lipopolysaccharide (LPS) and
endotoxins in the bloodstream can elicit a strong immune response, contributing to SIRS [8].
SIRS itself is a non-specific symptom and can be caused by a range of underlying etiologies,
including sepsis, so diagnostic tests are required to confirm the cause [9]. If a patient has sepsis
and remains untreated, they may progress to severe sepsis where their organ systems stop
working (such as renal or respiratory failure) as a result of the widespread dysregulation of
inflammatory cytokines, driven by the systemic infection. Assuming their failing organs can be
temporarily supported in an intensive care unit, they may progress to the final stage of the
continuum: septic shock. Septic shock occurs when multiple organs fail and hypotension that
cannot be reversed even with fluid resuscitation occurs, often resulting in death [6, 10].
Because of these severe effects of systemic infections, sepsis has a very high mortality rate,
ranging between 20-50% [6-8] for bacterial sepsis but it can be as high as 60% mortality if a
fungal pathogen is the cause. The incidence of sepsis is actually increasing as more and more
antibiotic resistant pathogens evolve, more immunocompromised patients emerge (due to HIV,
chemotherapy, organ transplants, etc) and more invasive surgical procedures are performed [11-
13]. It is currently the leading killer in intensive care units, causing 17% of total hospital related
deaths in the US [14]. In the United States alone, the incidence of sepsis has more than doubled
since 2000 and costs $15 billion per year to treat [14] The problem is even more devastating in
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the developing world where 98% of infant deaths due to sepsis occur, primarily due to lack of
diagnostic technologies [13].
- Local Infection escaping containment
- Begins to spread from its initial site
T  Heart Rate
-T Respiration Rate
- Abnormal Temperature
- Abnormal White Blood cell count
*Mortality Rate: 7%
* SIRS
- Cytokine Storm
- Widespread Inflammation
-Pathogens in bloodstream
- Mortality Rate: 16%
* Sepsis
- Organ dysfunction
- Diffuse intravascular coagulation
- Mortality Rate: 20%
- Systemic hypotension SNOK
- Low blood oxygen levels
- Multiple organ failure
- Mortality Rate: 46%
Figure 1.1 Stages of Sepsis
Sepsis starts as a local infection that the immune system cannot contain which spreads and
triggers a systemic inflammatory reaction that spirals out of control, culminating in multiple
organ failure, shock and death if the immune system and antibiotics cannot bring it under
control. The risk of death increases as the disease progresses [15]
1.2 Role of Diagnostics
I1
Can Result From:
* Infection
" Burns
- Trauma
- Myocardial
Infarction /
While the incidence of sepsis has increased steadily over the last thirty years, sepsis
diagnostic technology has changed little in the last 100 years. The primary challenge in
diagnosing sepsis is that the circulating pathogen load in blood is actually very low despite its
dramatic effect, typically ranging from I to 10 colony forming units (cfu)/ml of blood, although
some patients can have loads over 1000 cfu/ml [16]. Currently 'sepsis' is a clinical diagnosis that
results from the presence of bacteria (bacteremia) or fungi (fungemia) in the bloodstream.
However, the precise circulating pathogen load is poorly defined since current measurements are
relatively insensitive [10]. Currently sepsis is considered a clinical diagnosis because it typically
takes a minimum of 24 hours to confirm the presence of a pathogen, so the clinicians will begin
empirical treatment with broad spectrum antibiotics, which may or may not be effective
depending on the pathogen. Once the data on the causative organism is obtained from the
microbiology lab, the antibiotic treatment can be tailored to maximize its effectiveness. If this
information is available before the patient's organ system begin failing, they have a much better
chance of survival.
2 Automated Blood Culture 12-72 hours Infection present
3 MR"in & GaM sa 5M " 0*ntk O t+/-
4 Sub-culturing 24-48 hours
5 Plato hispeadoo I MinMtD PwbAb&Vnus
6 Automated AST and Gram 12-24 hours Species and susceptibilities
Negative Identification
Total: 1-7 days
Figure 1.2 Time required for sepsis diagnosis
This is the standard workflow for Mt. Auburn Hospital in Cambridge, MA, which handles about
10,000 samples per a year. Automated monitoring of the blood culture bottles has decreased the
diagnosis time slightly, but a dedicated lab and a trained staff are still required
Several studies have confirmed that a faster diagnosis time and therefore a faster time to
optimal antimicrobial therapy significantly decreases both the cost of treatment and the mortality
rate of sepsis [17]. The risk of death can increase as much as 9% for every hour that effective
treatment is delayed in sepsis [18, 19]. Faster diagnostic times also help prevent the use of
ineffective antimicrobial therapies, reducing the risks of creating drug resistant pathogens and
causing adverse drug reactions, which is particularly important for highly cytotoxic antifungal
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medications [20]. Treatment can be ineffective for many reasons including no coverage of the
pathogen (such as treating a fungal infection with antibiotics), resistance of the pathogen to the
medication, poor penetration of the drug into the infection site and underdosing [21]. Antifungal
medications are toxic enough that most clinicians will not start their use without definitive
microbiological data, so the patient can go days without effective treatment, contributing to the
higher mortality rate of fungal sepsis [19, 22]. Therefore, rapid confirmation of the clinical
diagnosis, particularly information on which antibiotics would be effective most effective, can
save lives and reduce treatment costs. However, the current diagnosis technologies available to
clinicians cannot provide this.
1.3 Current Diagnostics for Bacteremia and Fungemia
Blood culture is the current state-of-the-art method for detecting low levels of pathogens in
blood and has been so since the technique was first pioneered in the early 20th century. There are
several stages for blood culture (figure 1.2): first, a blood sample is collected aseptically into a
culture bottle containing growth media. Second, the sample is placed in an incubator and
monitored for signs of growth. Third, if any signs of growth appear, the cultured pathogen is
subcultured on several different types of agar plates to obtain a pure colony. Finally, the pure
colony is used to identify the pathogen and determine it's the antibiotic susceptibility of that
pathogen in an automated microdilution system. The entire process typically takes between 24 to
72 hours, depending on the pathogen and each different stage is vulnerable to errors. The
standard workflow for a medium-sized hospital is quite elaborate and illustrates why the process
is prone to errors and is difficult to implement in lower resource settings, where the need for
sepsis diagnostics are often much greater.
The initial collection of the blood sample is perhaps the most difficult part of the process
because sterile technique, proper growth media and timing can all be critical. Blood culture can
only detect viable pathogens in the blood, which are at their highest concentration immediately
after the septic patient spikes a fever [7]. Recent administration of antibiotics can bias the results
by killing the viable circulating bacteria in the bloodstream but not wiping out the focus of the
infection, creating a false negative result [23]. After a fever spike, two or more 10 ml samples are
collected from different veins in the patient's body after the skin at the venipunctures site has
been thoroughly sterilized by the phlebotomist performing the draw [24, 25]. A decision must
also be made about what type of culture bottles to use; whether the presumed pathogen requires
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aerobic, anaerobic or fungal media to culture; a decision that must currently be inferred from the
patient's history and physical symptoms. The sample volume must be reduced for children to 1
to 2 ml of blood, but in neonates it can be difficult to obtain even that much [26].
After collection, the blood culture bottles are placed in an incubator and monitored for
signs of metabolism (such as production of carbon dioxide). This step is also highly variable
because the optimal growing conditions and growth rate of pathogens varies from species to
species; some bacteria take as little as 12 hours while other organisms can take days and some
organisms cannot be cultured at all by this method, particularly if the wrong type of culture
media was used. Consequently, many patients suspected to have sepsis never have the diagnosis
confirmed [27]. If the bottle does show growth, the patient likely has an infection (assuming skin
flora did not contaminate the sample), but the clinicians still don't know what the organism is or
what will be treat it.
If the culture becomes positive, there are enough microorganisms to identify directly, so
they undergo Gram staining to differentiate between the two major classes of bacteria. The
positive culture broth is plated on a range of different agar plates that favor growth of particular
species or strains, which are then cultured for 24 hours so that individual bacterial colonies are
visible. Skilled microbiologists can identify the genus and species of some pathogens based on
its growth conditions and colony morphology, but antibiotic susceptibility testing (AST)
provides the most useful information for treatment.
AST produces the most critical information that clinicians require for treatment; which
antibiotics the pathogen is most vulnerable to. Bacteria from one of the subcultured plates are
suspended in media and then grown for between 4 to 24 hours in the presence of a range of
different antibiotics and several metabolic indicators that can be used to identify its species. This
process has been simplified with 96 well plates preloaded with the different reagents that can be
placed in an automated incubator with a built in colorimetric readout system (automated
microdilution system). Alternatively, the bacteria can be plated once more on dishes that contain
different antibiotic bearing discs or strips of paper to determine which of the drug impregnated
disks inhibits the growth of adjacent bacteria [28].
Blood culture diagnostic systems tend to be slow and expensive. The system typically
takes 24-72 hours to return a diagnosis in a disease that can progress in a matter of hours [29].
The diagnosis itself is not very reliable either, since the system is prone to false positives from
14
contamination and false negatives from incorrect culture conditions for fastidious microbes [7,
28]. In more than 50% of the cases where sepsis is strongly suspected, blood cultures never
return a positive reading [30]. The high cost of maintaining a microbiology lab currently means
that only hospitals with central labs can afford to operate one, since they require a large amount
of resources, a trained staff and millions of dollars in equipment to run. As a result of all these
shortcomings, clinicians often can never verify their diagnosis of sepsis and must rely on
epidemiology and experience to try and guess the best antimicrobial treatment (figure 1.3 a).
a) C)
4Prvidwsantibiotic prim"r
Cons *Multi day process -Only works for positive blood -Expensive Reagents
-Prone to contamination cultures -Sensitive to Contamination
and false positives -High start up costs -Many PCR inhibitors in blood
Figure 1.3 Pros and Cons of different methods to detect pathogens in blood
(a) Blood culture bottle and Petri dish with antibiotic impregnated disks used to test AST (Bauer-
Kirby procedure). Reprinted from [36] (b) Mass fingerprint of different bacteria from MALDI-
TOF analysis. Reprinted from [37](c) SepsiTest qPCR kit (Molzym) for identifying pathogens.
Reprinted from [38]
This microbiological culture detection method is used widely in several other types of
samples, ranging from concentrated platelets for transfusion to food samples [31, 32]. Platelet
concentrates are especially vulnerable to bacterial contamination because they must be stored at
room temperature, allowing uninhibited growth of bacteria in the concentrate bags, so they must
be screened for contamination with microbial cultures, a process which roughly cuts the useful
half life of the concentrates in half [33]. Detection of pathogenic bacterial contamination in food
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is also culture based; even PCR detection assays often require culture for 1-2 days to sufficiently
enrich the bacteria from food for detection, during which time the food must be stored at great
expense [34, 35].
Faster, cheaper and more reliable methods for detecting rare bacteria in complex samples
such as blood samples could potentially save millions of lives around the world and billions of
dollars, so a variety of approaches to speed up the process are currently being investigated. These
alternatives are also running into the difficulty of detecting fewer than ten pathogens among
billions of red blood cells and millions of white blood cells per milliliter of blood. It's roughly
equivalent to trying to find a single infectious grain of sand somewhere in four dump truck loads
from the beach.
1.4 Alternative Diagnostic Methods Being Researched
Mass spectrometry and molecular diagnostics such as polymerase chain reaction (PCR) are
currently believed to hold the future of sepsis diagnostics, but both systems have had difficulty in
overcoming the signal to noise created by low pathogen counts in human blood. Biomarkers
have also been investigated but their role in sepsis still remains undefined and highly variable
[10, 39], making them less suitable as a potential replacement for blood culture.
Mass spectrometry offers a highly sensitive method for identifying pathogens. It has been
found that all bacteria have 'mass fingerprints' which can be detected with matrix assisted laser
desorption/ionization time of flight (MALDI-TOF) Mass Spectrometry. The reading detects and
analyzes molecules between 2,000 to 20,000 Daltons, which are mostly made up of high
abundance ribosomal proteins that vary from species to species, creating the specificity of the
fingerprint [37]. A single machine can run several tests per hour at very little cost per a sample,
although the machine itself is quite expensive [40]. The main limitation of mass spectrometry is
that all the current systems require at least 5000 bacteria (although 100,000 or more is preferred
for a better signal) in the sample matrix for a high enough signal to noise ratio to accurately
determine the species, particularly if the sample is polymicrobial [41, 42]. This has limited mass
spectrometry to identifying pathogens from positive blood cultures, which is still highly useful
since it reduces the average diagnostic time by 26.5 hours at a comparable cost of existing AST
methods, but it still suffers from some of the same limitations as standard blood culture [42-47].
Mass spectrometry is also a reliable method for differentiating between different types of yeasts,
whose macro and microscopic characteristics are highly subjective and DNA extraction from
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fungi for PCR is difficult due to their extremely tough cell walls [48-51]. So mass spectrometry
is a very promising method for identifying pathogens out of blood cultures, but the high bacteria
count required for a reliable mass fingerprint makes it unlikely it can detect pathogens directly
from blood samples, since even in very septic patients the size of the blood draw required to have
a sample with 5,000 microbes or more would require a very large volume of blood (figure 1.3
b).
PCR has the ability to amplify a single gene several million-fold and is capable of detecting
single cells. Because this assay relies on DNA, it can pick up not only viable pathogens, but also
dead ones or even phagocytosed pathogens, giving it a larger population to detect than is possible
by blood culture [52]. Universal primers targeting highly conserved regions of 16s ribosomal
DNA for bacteria and internal transcribed spacer region for fungi, are available [9, 53].
Therefore, with one or two primer sets, it should be possible to amplify DNA from nearly all
known microbial pathogens. The amplified PCR product can then be sequenced to determine the
species of the microbe. Microfluidic PCR systems can completely run an entire PCR reaction in
less than 30 minutes using far less reagents than bench top systems, offering a truly rapid
detection method [54-63]. However, several practical difficulties of working in blood have so far
prevented the full potential of PCR diagnostics from being realized.
Extracting pathogen DNA currently has low efficiency and the reaction chemistry of PCR
itself is delicate and vulnerable to a large number of inhibitors which abound in blood [28], so
sample preparation has been problematic for both bench top and microfluidic systems [55, 59,
62, 64-68]. Furthermore, anticoagulants, hemoglobin, calcium, human DNA and
immunoglobulin G all interfere with the reaction as well, and these are millions of times more
abundant than the target pathogen in most blood samples [28, 69]. A robust sample preparation
method to remove the majority of inhibitors found in blood is of paramount importance to make
PCR a viable sepsis diagnostic technology, but no robust system has yet emerged. Some
commercial companies have developed methods such as VYOO and MolYsis to try and enrich
pathogen DNA in the sample, but none are currently approved for clinical use by the FDA. The
MolYsis sample prep kit is arguably the most reliable, but its sensitivity is 50 cfu/ml, which is
not sufficient to detect bacteria in the majority of septic samples [21] (figure 1.3c). Some groups
have reported reaching down to 1 cfu/ml sensitivity through a variety of techniques such as
nested PCR but reproducibility has been problematic [53]. General opsonin magnetic beads
17
potentially offer a simple way bind, concentrate and purify pathogens out of blood, greatly
increasing the reliability of PCR for use as a diagnostic.
1.5 Binding of Rare Cells
The use of immunomagnetic beads for binding and concentrating a large variety of cells and
molecules have been growing in recent years. They were first used in 1977 when Molday et al.
used lectin-functionalized iron oxide particles to bind and isolate red blood cells [70]. The
majority of beads now used for this form of purification are superparamagnetic, meaning that
they become magnetized when placed in a magnetic field but unlike ferromagnetic materials
such as iron, they are not magnetic when the magnetic field is removed [71]. This makes it very
easy to resuspend the beads in solution after magnetic concentration, which has led to their
widespread adoption.
The force on these beads created by the magnetic field is directed parallel to the local
magnetic field lines and proportional to the strength of the local magnetic field gradient [72].
Once the beads are attached to target cells, they can be used to apply a variable amount of force
to a cell for purification or mechanical testing [73-75] or even more delicate operations such as
rotation [76, 77]. The majority of beads used for biological applications are on the scale of
micron or nanometers, meaning that they have a very large surface area to volume ratio, which
gives rise to their greatest strength. A large number of beads can be added into a large fluid
volume and mixed so that the beads rapidly probe every microliter of that volume and come in
contact with its entire contents in a matter of minutes. If the large surface area of the beads is
functionalized with a protein that can bind to a population of interest, such as a pathogen, this
population will be rapidly tagged with magnetic beads that can then be magnetized to pull that
population out of the tagged fluid [74, 78].
1.6 Concentration of Magnetically Tagged Cells
Once the population of interest is magnetically tagged, several bulk and microfluidic
separation systems are available for purification. The majority of bulk systems are essentially a
test tube rack with permanent magnets in place next to the tubes that can generate enough force
to pull out the micron scale beads such as Invitrogen Dynabeads, popular for binding mammalian
cells. Miltenyi Biotech produces the MACS separation column, which is a column packed with
steel wool that generates magnetic gradients strong enough to capture nanometer scale beads
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when magnetized [79]. Microfluidic systems with external permanent magnets or micro
fabricated electromagnets offer much finer control over separation conditions than bulk systems
and have been widely employed to study the finer aspects magnetic cell separation [78, 80-83]
with both simulations and experimental observations. Precise calculations are difficult because
magnetization, convection, diffusion, collision theory and reaction chemistry all need to be taken
into account when dealing with magnetically tagged cells, which restricts the majority of
problems to finite element solver programs using either particle tracking or continuum models to
represent the beads and bound cells [84-86]. The models can then be confirmed with experiment
in the microfluidic device. The primary advantage of a microfluidic separation system is that it
can offer a way to transition bulk bead binding to a small volume for detection because the
magnetically tagged pathogens can be concentrated in a small area on the device, going from
milliliter volumes in a tube to microliter volumes in a microfluidic chip.
Since 1977, several groups have employed primarily antibody-functionalized beads for a
wide variety of different applications, including isolation of circulating tumor cells [73, 87, 88],
endothelial progenitor cells [75], CD56+ cytotoxic cells [89], E. coli [90], and C. albicans [91]
from blood and even bacteria out of food samples [92]. The Ingber Lab's previous work with E.
coli and C. albicans showed that magnetic beads could be used to reliably remove pathogens out
of human blood. Virtually any population to which an antibody or other binding protein can be
created is a candidate for this magnetic tagging method, giving it a great deal of flexibility for
biological assays. However, the use of antibody functionalized beads for a diagnostic system to
bind rare pathogens out of a complex sample such as blood is intrinsically limited because the
beads can only bind a limited group of pathogens. This would work well if there was only one
population of interest, such as tumor cells or methicillin resistant S. aureus (MRSA), but is not
sufficient for sepsis diagnostics, which must be able to pick up at least 20 different species.
General opsonins are single molecules that have the ability to bind a wide range of different
target cell types, so magnetic beads coated with these molecules should overcome this limitation.
1.7 Generic Opsonins
Antibodies such as immunoglobulin G are important effectors of the adaptive immune
system; this system is a relatively recent evolutionary development. General opsonins form an
integral part of the primitive immune system, which evolved millions of years before the
adaptive immune system and relies heavily on a class of sugar binding molecules called lectins
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for defense against invading organisms [93]. In many invertebrates such as the Japanese
horseshoe crab Tachypleus tridentatus [94], the silkworm Bombyx mori [95], and the cockroach
[96], the primitive immune system is their primary form of defense. In mammals such as
humans, the primitive immune system and its lectins form the first line of defense, giving time
for the adaptive immune system to produce specific antibodies against an insult [93, 97]. The
lectins of the innate immune system play key roles in the opsonization, activation of prophenol
oxidation, phagocytosis, agglutination, activation of complement and lysis of foreign cells [98-
100]. Many lectins can recognize pathogen associated molecular patterns (PAMPs) such as
peptidoglycans, lipoteichoic acid and lipopolysaccharide, which are produced by bacteria but not
by eukaryotic hosts. There is a wide range of lectins available that can bind to bacteria, but
relatively few of them are suitable for working in blood, since most invertebrate and plant lectins
see mammalian red blood cells as foreign and will attach to them, which has made some useful
for blood typing [101-103]. To find a general opsonin that could bind a wide range of pathogens
but is also compatible with human blood, we turned to the human primitive immune system, of
which the most prevalent molecule is a polymer called mannose binding lectin (MBL), sometime
also known as mannan binding lectin (figure 1.4a).
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Figure 1.4 Structure of MBL
(a) Full polymeric form of the protein with MASP's attached to the collagen-like stalks, which
are responsible for sensing MBL binding and initiating the complement cascade, coagulation
and phagocytosis. (b) Single monomer of MBL. The CRD contains the actual binding pocket for
the target sugar residues and the collagen domain and cysteine rich domain control
polymerization of the protein. (c) Three monomers combining so that their collagen-like domains
form a triple helix. These trimers assemble into the full protein.
MBL was first discovered in serum as a molecule that could inhibit influenza A virus, but it
was not actually identified for another 40 years until immunologists began to realize the
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importance of the primitive immune system [104]. The molecule itself is part of the calcium-
dependent lectin family, along with surfactant proteins A and D (SP-A and SP-D) [99]. It is
primarily a serum protein but is also found in amniotic fluid, nasal secretions, middle ear fluid
and inflamed sites such as rheumatic joints [105]. MBL is able to bind and recognize the
terminal sugar residues on a wide range of bacteria, fungi, viruses and some protozoa, but not
human cells, unless they are damaged or mutated [106, 107]. The basic binding subunit of MBL
is composed of a carbohydrate recognition domain (CRD), which is on the end of a long
collagen-like stalk that twines together with two other strands to form a triple helix with a cluster
of the three CRD's at the end [108] (figure 1.4b-c). Oligomers of these triple helices (usually a
tetramer or more) attach together forming a bouquet-like arrangement that makes up the
functional MBL protein [109]. MBL associated serine proteases (MASPs) bind to specific sites
on the collagen-like stalks and can sense the conformational change in MBL when it binds to a
pathogen and then proceed to cleave and activate complement and other effector molecules
[110]. The CRD contains a highly conserved amino acid sequence that has the ability to
recognize and bind to hydroxyl groups on sugars such as D-mannose, L-fucose and N-acetyl-D-
glucosamine (GlcNAc) found on pathogens [111, 112]. Normal human cells have D-galactose or
sialic acid as the terminal sugars on most of their glycoproteins, which fit poorly in CRD,
allowing differentiation of self from non-self [105]. In addition to sugar structures, it has been
shown that MBL can also bind to phospholipids [113], nucleic acids [114, 115], and non-
glycosylated proteins, a feature which probably plays a role in MBL's ability to bind and help
clear apoptotic and necrotic cells. These dead or mutated cells expose neo-epitopes not found on
healthy human cells. So unlike invertebrate and plant lectins, MBL does not bind to human cells
and unlike surfactant proteins A and D (which are usually found in the alveoli of the lung), it has
evolved specifically to function in blood, making it well suited for magnetically opsonizing
pathogens in blood.
The actual binding strength of each CRD in MBL is relatively weak (only Kd of 10 ), but it
overcomes this by using avidity-based binding, with several of the CRD's from a single MBL
attaching at once to the surface of the pathogen, giving the protein binding strength comparable
to most antibodies on many pathogens [109, 116-118]. Recent studies have shown that MBL can
bind to fungi such as Candida and Aspergillus species and bacteria such as S. aureus, non-
encapsulated Listeria monocytogenes, Haemophilus fluenzae B, Neisseria meningitidis,
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Neisseria cinera, Neisseria subflava, streptococci, Escherichia coli, and Neisseria meningitidis
serogroup A [105, 109]. The one class of pathogens that MBL has difficulty binding is
encapsulated pathogens such as N. meningitidis, H. influenza, Streptococcus agalactiae and
some Salmonella strains [3, 106] because these organisms shield their terminal sugar residues so
there are fewer targets for MBL to bind. MBL serum deficiency, caused by mutations in the
MBL gene, has been shown to increase the risk of mortality in pneumococcal infections and the
risk of developing serious complications in sepsis such as disseminated intravascular coagulation
(DIC) [119, 120]. Phase I clinical trials are currently in progress to see if recombinant MBL
therapy can reduce the risk of infections in deficient patients [121]. So, MBL is a single, blood
compatible molecule that can bind to E. coli, S. aureus, and Candida albicans, three of the major
pathogens implicated in sepsis and many more besides. We propose to take advantage of this
versatile molecule, which can bind pathogens from different species, geneses, or even kingdoms,
and attach it to magnetic beads. This should provide a single set of beads that can bind to the
majority of pathogens that can cause sepsis, forming the foundation for a rapid diagnostic
system.
1.8 Summary
Sepsis is a serious problem in hospitals around the world, taking thousands of lives and
costing billions of dollars every year, and it is projected to become more common as more
immunocompromised patients and drug resistant pathogens emerge. In some patients, the disease
can progress from fever and chills to organ failure and shock in a matter of hours, creating a
great need for a rapid diagnostic that can allow clinicians to implement effective antimicrobial
treatment as quickly as possible. However, the current, state-of-the-art blood culture
identification and antibiotic susceptibility testing systems fall short of this mark, typically taking
between 24-72 hours for most pathogens. As many as 50% septic patients never have their
infection confirmed due to the poor sensitivity of these culture-based approaches. Technologies
such as PCR have the potential sensitivity to detect pathogens directly in blood if the inhibitors
and contaminating human DNA in blood can be removed. Towards this end, I have worked with
other researchers at the Wyss Institute to develop and characterize general opsonin magnetic
beads which can bind to pathogens in blood, giving us the ability to concentrate them out of
blood for analysis and identification. We believe that this bead technology can create a robust
sample preparation method for isolating pathogens out of blood for a plethora of different
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detection technologies that can avoid the pitfalls of blood culture by directly detecting pathogens
in blood. In the remainder of this thesis, I will discuss my progress in characterizing their ability
to bind a wide range of different pathogens, developing a microdevice that can concentrate and
display tagged pathogens for optical detection and using these beads to concentrate and purify
pathogens out of blood and other complex samples for rapid identification with PCR.
1.9 Aims
C)
a)
b)
d)
General opsonin magnetic beads to bind
pathogens
Optical detection and PCR
identification of captured pathogens
Figure 1.5 Using general magnetic opsonins of detect pathogens in blood
(a) Blood containing pathogens (green) enter the detection system (b) Magnetic beads coated
with MBL bind to the pathogens but not the blood cells (c) A magnet concentrates the beads and
tagged pathogens out of the blood (d) The concentrated pathogens can be detected optically or
with PCR, creating a rapid sepsis diagnostic. Gel image reprinted from [122]
Aim 1: To develop magnetic opsonins that bind pathogens with high efficiency (figure 1.5a-b)
1. Develop MBL coated magnetic beads
2. Show that MBL beads bind to wide range of pathogens in saline
3. Show that MBL beads bind to pathogens in blood
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Aim 2: To engineer devices that concentrate and visualize captured pathogens (figure 1.5c-d)
1. Develop a device that can isolate magnetically tagged C. albicans from a large volume of
blood
2. Develop a method to optically detect the presence of captured fungi in the device
3. Investigate whether the system can detect other pathogens, such as S. aureus
Aim 3: To develop tools to identify the specific type of pathogen captured (figure 1.5c-d)
1. Develop an effective method to remove and concentrate magnetically-tagged bacteria
from blood
2. Use the FcMBL beads to isolate magnetically tagged bacteria out of blood for PCR
identification
3. Compare FcMBL sample preparation method to commercial method
4. Show the sample preparation method can work for a range of different complex samples
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Chapter 2 General Magnetic Opsonins
2.1 Introduction
Our lab previously developed magnetic beads coated with specific antibodies against
pathogens which allowed us to bind C. albicans and E. coli and concentrate them from blood
[90, 91]. The beads have the ability to rapidly circulate through milliliter-size fluid volumes and
bind to their target pathogen, giving us a magnetic handle on the pathogens which we can then
exploit to concentrate the pathogens for direct identification rather than having to rely on
culturing the organisms first to obtain enough for identification, as is currently done in the clinic
[28].
However, for sepsis, the species of the organism causing the illness is not known, so species-
specific immunomagnetic beads are of very little use in binding the causative pathogen, which
can be one or more of over 20 species [109]. To overcome this limitation of what is otherwise a
very promising method to rapidly isolate rare pathogens out of blood samples, the magnetic
beads were coated with a general opsonin derived from the innate immune system to give us a
single set of beads that can bind a wide range of pathogens. For this purpose, mannose binding
lectin (MBL) was selected, which is a circulating serum protein that can recognize the sugar
motifs found on a wide range of human pathogens, including gram positive and negative
bacteria, fungi, protozoa and some viruses [3]. The primary advantage of human MBL over other
lectins is that it will not bind to normal blood cells, which is the case with lectins derived from
non-mammalian species [102, 103]. By coating this protein rather than a species-specific
antibody onto the magnetic beads, a much more versatile capture method is created, giving us a
single set of beads that can bind to the majority of pathogens recognized by the human body.
Therefore, prior knowledge of the causative organism in a septic patient is not required to bind
and concentrate it from blood for identification. Consequently, we hypothesized that the MBL-
functionalized magnetic beads could form the core technology for a rapid sepsis diagnostic
system.
The remainder of this chapter will discuss the results of my research into developing and
characterizing MBL-functionalized beads for binding pathogens in both saline and blood. We
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began by adapting the procedure we had used to create antibody beads for use with commercial
wild type MBL (WtMBL) for capturing a range of pathogens and compared it to a recombinant
form of the protein (FcMBL) produced in house at the Wyss Institute. Once we had established a
basic recipe for producing the MBL beads, I then investigated how to optimize binding in saline
by varying the bead size, concentration and MBL density on the beads with a variety of pathogen
species. I then used the knowledge gained from binding in saline to study pathogen binding in
blood while dealing with the additional challenges posed by phagocytosis, coagulation and high
hematocrit levels of blood. From these investigations I established a set of basic conditions for
binding both bacteria and fungi in saline of blood with general opsonin beads, which is then
exploited in later chapters to concentrate pathogens out of blood for direct detection and
identification. This work formed the laid the groundwork for experiments that other researchers
at the Wyss have used to show FcMBL beads can capture a wide range of species in blood.
2.2 Materials and Methods
2.2.1 Functionalizing Magnetic Beads
One im or 128 nm superparamagnetic streptavidin beads were washed with 1% BSA in
PBS and incubated with 25 ptg protein/mg beads (MyOne Dynabeads streptavidin T 1, Invitrogen
or Bio-Adembeads, Ademtech). Either used WtMBL (Sino Biological Inc) or recombinant
FcMBL produced in house at the Wyss Institute on the beads was used. After the MBL was
conjugated to the beads, the remaining streptavidin was blocked with 50 Pl of biotin solution
(Endogenous biotin blocking kit, Invitrogen). After the blocking was complete the beads were
resuspended and diluted to 5 mg beads/ml in 1% BSA in PBS with 10 mM EDTA and stored at
4*C for up to four weeks.
2.2.2 Pathogen Stocks
Liquid cultures of C. albicans (donated by Brown et al [123]), C. parapsilosis, S.
cerevisiae, P. pastoris, E. Coli (ATCC 8739), S. aureus (clinical isolate) and Klebsiella
pneunoniae (clinical isolate) where grown overnight in an Innova 42 incubator (New
Brunswick Scientific) with 100 ml of media in an erlenmeyer flask, circulating at 250 rpm.
Bacteria were grown at 37"C in LB broth and fungi were grown at 30'C in YPD media. Samples
of all pathogens were centrifuged and resuspended in PBS with 20% glycerol and aliquoted into
PCR tubes for long term storage at -80'C. The average pathogen concentration in each aliquot
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was determined by performing quantitative microbiological plating on serial dilutions of five
aliquots chosen randomly from each batch.
2.2.3 Binding Quantification (Depletion Assay)
Binding quantification was carried out in micro centrifuge tubes containing 500 or 1,000
gl of sample containing the pathogens of interest. For flow cytometer quantification, the
pathogen load in the sample was ~10,000 to 1,000 cfu/ml while for the plate based quantification
the concentration was -1,000 cfu/ml. Three samples were made for each condition, one
experimental with MBL beads, one with non-functionalized beads to assess non-specific
adhesion and one with no beads to check for growth during the experiment. All three samples
received the same treatment during mixing and analysis steps of the experiment.
a) b) c)
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Figure 2.1 Procedure for Depletion assay to measure bead binding
(a) Sample containing bound and unbound pathogen after MBL bead binding is complete (b)
Sample is placed in magnetic separator rack, pulling the beads and bound pathogens out of
solution (c) A portion of the sample fluid is removed and the concentration of unbound
pathogens analyzed using the flow cytometer or plating.
The samples were maintained at 4*C and placed in a Hula shaker (Invitrogen) for 20 minutes,
then transferred into a DynaMagTM-2 Magnet separator rack (Invitrogen), unless otherwise
specified, for 10 minutes. At the end of this time, the tubes were left in the rack and 100 pl of the
depleted fluid (containing any pathogens not captured by the MBL beads) was removed for
analysis on the flow cytometer or plate based methods (figure 2.1 a-c). Binding was quantified
by taking a ratio of the pathogen concentration in the experimental and no bead tubes for each
sample. Non-specific adhesion of the pathogens was calculated by comparing the depletion
between the blank bead sample and the no bead sample.
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For flow cytometer measurements (used for fungi in initial experiments), a known amount of
CountBrightTM absolute counting beads (Invitrogen) and 25 pM of calcofluor white stain
(Sigma) to stain the fungi was added to the depleted and positive control samples and then
processed through a LSR II Fortessa flow cytometer (BD). Flow cytometer quantification was
only used for fungal species because the smaller bacteria were more difficult to reliably detect
with the instrument while plate based analysis was used for both bacteria and fungi. The
counting beads were used to determine the volume of fluid processed and derive the
concentration of the fluorescently stained fungi in the starting sample.
Quantitative microbiological plating was employed to determine the concentration of both
bacteria and fungi at concentrations at or below 1,000 cfu/ml. One hundred millimeter Petri
dishes (BD) were pre-warmed in the incubator for 30 minutes before use (LB agar plates at 37*C
for bacteria, Potato Dextrose Agar plates at 30*C for fungi). For quantification, 100 p of the
depleted fluid was spread on the plate using EZ-Spread plating beads (Genlantis), then
transferred upright into an Innova 42 incubator (New Brunswick Scientific), at 37C for bacteria
or 30'C for fungi, and given one hour to dry before being inverted and stacked. Aerobic bacteria
were cultured for 24 hours and fungi were cultured for 48 hours before the colony number was
analyzed using a Flash and Grow system colony counter (Neutec).
2.2.4 Recombinant MBL (FcMBL) Production
FcMBL was designed as a homodimeric fusion protein with the hinge, CH2 and CH3
sequences of human IgG 1 fused to the neck and CRD regions of human MBL. Then the FcMBL
plasmid was transiently transfected into Hect 293F cells. The secreted FcMBL was isolated from
the culture medium using FpLC purification. The protein was then biotinylated using aminooxy-
biotin (Biotium). For full details see Super et al [124].
2.2.5 Calcium Dependence
These tests were a variation of the standard depletion assay with flow cytometer analysis. In this
case, C. albicans were stained with 25 p.M calcofluor white and added to buffer TBS-Tween 20 buffer
containing 0, 1, 2, 3, 4, 5, and 10 mM of calcium chloride in microcentrifuge tubes. Fifty pg 1 pm
WtMBL beads/ml were added to the sample and mixed in the Hula Shaker (Invitrogen) for 20 minutes
before being transferred to the magnetic separation rack for 10 minutes. Then flow cytometer analysis
was carried out on 100 pl of the depleted fluid. After this, 0.25 M Ethylenediaminetetraacetic acid
(EDTA) was added to the sample tubes to chelate the free calcium from the buffer and the tubes
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were mixed in the shaker for an additional five minutes before magnetically separating the
samples again and analyzing the depleted fluid again for fungi released by the EDTA chelation
process.
2.2.6 Binding in Blood
2.2.6.1 Blood Collection and Separation into Different Components
Fresh blood samples were collected from healthy adult volunteers by a trained
phlebotomist at the Wyss Institute into a range of vacutainers (blank discards, serum, sodium
heparin, EDTA) depending on the assay being performed. Serum tubes were placed in a 37 0C
incubator for 1 hour, after which the liquid portion of the sample was removed, centrifuged at
200xg for 20 minutes and the serum transferred into a new tube, ready for the experiment.
Plasma was generated from sodium heparin treated vacutainers by centrifuging the blood
at 200xg for 20 minutes. The plasma was first transferred to a new tube, and then the white blood
cell buffy coat was aspirated and discarded from the sedimented red blood cells, which were then
resuspended in PBS. The plasma was spun again at 500xg for 10 minutes. The platelet poor
plasma was transferred to a new tube and the platelet pellet resuspended in the same volume of
PBS as the plasma (preserving their physiological concentrations). These components were then
used for different binding tests. This gave serum, platelet poor plasma, platelets and red blood
cell solutions that could be used for different experiments
2.2.6.2 Dilution Experiments
Blood was collected from healthy volunteer donors into a 10 ml sodium heparin
vacutainer and maintained at 4"C during the experiment. Samples of undiluted blood, blood
diluted 1:1 with TBS-Tween 20 buffer and blood diluted with 1:9 with TBS-Tween buffer were
compared, each containing 1,000 cfu/ml of C. albicans. Both lysed (containing 1% Triton X-
100) and unlysed samples were run at each condition. Ten pg of 1 pim FcMBL beads per
milliliter were added to the sample and mixed for 20 minutes in the hula shaker (Invitrogen). A
standard plate-based depletion assay (see 2.2.3) was used to analyze the binding results. After
the plating for the depletion was completed, the captured beads and pathogens were washed and
examined under phase contrast on an inverted microscope (Leica).
2.2.6.3 Phagocytosis Assay
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Fresh heparinized donor blood was split into two halves, with one half being held at 40C
for the duration of the experiment and the other half being held at 250C. WtMBL beads (25 pig of
1 pm/ml) were added to the samples and before they were placed in the Hula Shaker for 0, 30, 60
and 90 minutes, after which time the samples were placed in a magnetic separation rack for 10
minutes. The blood was then aspirated from the tube and magnetic beads and any retained human
cells were resuspended in 200 p1 of TBS-Tween 20 buffer and analyzed on the microscope. The
relative number of white blood cells that had bound or phagocytosed the magnetic beads at each
time and temperature were compared to ascertain how effectively cooling could slow the
phagocytosis process.
2.2.6.4 Anticoagulant Experiments
To determine the effectiveness of adding additional anticoagulants to blood at increasing
binding, different concentrations of salicylic acid (active ingredient in aspirin) in blood were
investigated. Initially 0, 100 and 1,000 pg salicylic acid/ml were added to heparinized blood and
checked on the microscope if it could prevent clot formation on the beads after magnetic pull
down (because it was difficult to image the beads in blood before magnetic pulldown). The effect
of adding 1,000 pig salicylic acid/ml on binding of C.albicans with 20 pig 1 pm FcMBL beads/ml
in undiluted blood was then investigated. Both lysed (with 1% Triton X- 100) and unlysed bloods
were run using a standard depletion plate-based assay.
Binding was compared in heparinized and recalcified EDTA blood. Blood from healthy
human donors was collected into both heparin (control) and EDTA vacutainers. Both types of
blood were diluted 1:1 with TBS-Tween 20 and had 1,000 cfu/ml C. albicans added. FcMBL
beads (20 pg 1 im beads/ml sample) and 0, 5, or 10 mM calcium were added to the samples,
which were then immediately placed in the Hula Shaker for 20 minutes. Next the samples were
transferred to the magnetic rack for the depletion plating assay (see 2.2.3) to measure fungi
binding in the different samples.
2.2.6.5 Binding Time
To ascertain the required binding time for magnetic beads in blood, FcMBL beads and C.
albicans were added to blood to measure the percent of pathogens bound over 20 minutes of
mixing time. Five micrograms of beads per milliliter sample were added into 10 ml diluted (1:1
with TBS-Tween 20) and undiluted blood samples before the tubes were placed in a Hula Shaker
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for mixing. The mixing was paused periodically and 500 ptl samples removed at specific time
points. The 500 pLl samples were immediately placed into a magnetic rack to pull down the
beads and stop the binding reaction. The concentration of unbound pathogens in the depleted
fluid from the different time points was assayed using depletion plating.
2.2.6.6 Bead Concentration
To determine the optimal bead concentration for 1 pm FcMBL beads to bind to C.
albicans in blood, a binding depletion assay was carried out in fresh donor blood (both undiluted
and diluted 1:1 with TBS-Tween 20) with a bead concentrations ranging from 10 to 50 pg/ml
sample.
2.2.6.7 Magnetic Separation Different Beads
The binding of bacteria was tested with the different bead types. S. aureus, E. coli and K.
pneumonia in diluted, recalcified EDTA blood with 25 pig of 1 pim, 128nm or both beads types
per ml sample. The samples were given 20 minutes to bind before being placed in a magnetic
rack for 10 minutes for separation.
Separation of C. albicans from diluted heparin blood was assayed by adding C. albicans
to the blood and 33.3 pg of 1 pm or 128 nm beads/ ml sample. The beads were given 20 minutes
to bind in the inverting shaker before the tubes were placed in the magnetic rack for 10 minutes.
Over the course of the ten minute separation, 100 pl aliquots were removed and plated to
determine the percent of pathogens that had been separated out over time.
To get a better idea of how well 128 nm beads worked for removing bound bacteria from
blood, the binding and separation of the S. aureus was tested with 50 pg 128 nm beads/ml
sample. Different amounts of mixing time were investigated. Samples for each time point were
prepared in separate microcentrifuge tubes, mixed for a set amount of time (0, 10, 20, 30, 60
minutes) and then placed in the magnetic rack to stop the binding reaction. The samples were in
the rack for 10 minutes before being plated to measure the pathogen depletion. Two controls
were run; one in saline and the second with pre-bound S. aureus added into the blood (this
checked to make sure that the bound pathogens were being separated with the rack) and mixed
the pathogens with the beads for up to one hour. To study the effect of the cellular fraction of
blood on binding, the same experiment was run using heparinized plasma instead of blood.
31
2.3 Results
2.3.1 Binding in Saline
2.3.1.1 MBL vs. Antibody beads
After functionalizing 1 pm superparamagnetic beads (Dynabeads, Invitrogen) with
WtMBL, I compared them with antibody functionalized beads for binding two different species,
C. albicans and closely related C. parapsilosis. Anti-Candida albicans antibody beads were able
to capture the majority of C. albicans out of buffer, but capture dropped to less than 20% for the
closely related C. parapsilosis species in buffer (figure 2.2a). The WtMBL beads were tested
with a range of bead concentrations (figure 2.2b). Capture increased with increasing bead
concentration, starting at 20% for both species at 10 pg beads/ml sample and plateauing at 95%
capture at 100 pg beads/ml.
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Figure 2.2Antibody vs. MBL beads
(a) Binding of C. albicans (Ca) and C. parapsilosis (Cp) with Anti -C. albicans and WtMBL 1
pum Beads: 100 ,ug 1 pm beads/ml. Poor binding of Anti-C. albicans beads to closely related C.
parapsilosis while WtMBL beads to both is good (b) Binding of C albicans (Ca) and C.
parapsilosis (Cp) with different concentrations of WtMBL 1 pm Beads: Binding is similar with
both species and increases with increasing bead concentration, saturating around 95% binding
with 100 ,ug beads/ml sample.
The surface area of 100 pg of the 1 pm beads is 0.16 M2, meaning that if the beads are
uniformly suspended in one milliliter of fluid, nothing in the fluid will be more than -6 jim away
from the surface of a bead, greatly limiting the distance over which the beads need to diffuse or
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convect for binding to occur. The Stokes-Einstein equation can be used to estimate the diffusion
coefficient for a spherical bead: [125].
D- KBT
61T7r
(2.1)
Where D is the diffusivity of the particle, KB is Boltzmann's constant, T is the absolute
temperature, 11 is the viscosity of the fluid and r is the radius of the bead. The amount of time (t)
required for a bead to randomly diffuse a set distance x can be estimated with the following
equation [125]:
x 2
t Oc -2D
(2.2)
The diffusivity on a 1 pm bead is on the order of 4.3x 10- 3 m2 /s, meaning it will diffuse across 6
gm in approximately 60 seconds, allowing the bead surfaces to rapidly probe the entire fluid
volume in a matter of minutes, giving us the binding ability of liquid chromatography with a
great deal more flexibility since the beads and tagged pathogens can be easily manipulated, while
a high pressure liquid chromatography columns cannot. Given these estimates and the ability of
MBL to bind a range of different pathogens, these general opsonin magnetic beads could form
the basis of a robust sepsis diagnostic system and were further characterized.
2.3.1.2 Calcium Dependence
Calcium ions play a key role in stabilizing the tertiary structure of the carbohydrate
recognition domain (CRD) of MBL, which is the part of the MBL protein responsible for
actually binding to exposed sugar groups [111]. Therefore, the effect of calcium concentration on
binding of pathogens with the WtMBL beads was investigated (figure 2.3). I tested calcium
chloride concentrations from 1-10 mM and found that binding saturated at 95% ± 5% capture for
C. albicans under all concentrations. Less than 10% binding of the fungi was observed when no
calcium was added to the buffer. This result offered a relatively simple way to differentiate
between MBL and non-specific binding: MBL binding activity of the beads should be calcium
dependent (without calcium the carbohydrate recognition domains in MBL cannot establish
stable binding) while non-specific binding should be constant even with no calcium in the buffer.
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From this point on saline experiments were carried out in Tris Buffered Saline with 1% Tween
20 and 5 mM calcium chloride to ensure that there was always sufficient calcium in the buffer.
Calcium dependence could offer a simple way to reverse the binding and release the
pathogens from the beads on demand since the stability of the binding pocket in the CRD is
reduced once the calcium is removed. However, I found that the binding of WtMBL beads to C.
albicans was very stable with less than 30% ± 16% of the pathogens being released even when
0.25M EDTA was added to the buffer to remove all free calcium ions (figure 2.3). Chemically
denaturing the MBL on the beads with high pH could effectively release the bound pathogens,
but this was not compatible with the majority of the analysis techniques (such as
immunofluorescence staining) I wanted to use to detect magnetically tagged pathogens. Porter et
al. found that adding a large amount of competing sugars could release bacteria bound to lectin
functionalized beads [126] and other members of the Wyss Institute found that a large proportion
of E. coli could be released with EDTA chelation of calcium [124], suggesting that this elution
method is dependent on the affinity of MBL for a specific species or strains, making it unreliable
for use in a diagnostic system to detect an unknown pathogen.
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Figure 2.3 Calcium Dependence of MBL Binding
Binding of C. albicans with 50 pg 1 pm WIMBL beads/mi sample. Binding requires 1 mM of
calcium be present in the buffer. Addition of 0.25 M EDTA depletes the ionic calcium from the
buffer but fails to elute the pathogens off of the beads, causing less than 25% to detach. n=2,
error bars: SEM
2.3.1.3 MBL Bead Binding to Other Pathogens
I carried out further investigations with a wider range of fungi and bacteria to
characterize the diversity of the MBL bead binding in buffer. The 1 pm WtMBL beads could
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bind well to all the fungal species tested (Candida albicans, Candida parapsilosis,
Saccharomyces cerevisiae and Pichia pastoris) with binding observed between 90-95% ± 3% for
the fungi in buffer with 10 pg bead/ml sample (figure 2.4a). Three species of bacteria were
tested: S. aureus as a representative Gram positive bacteria implicated in sepsis and Escherichia
coli and Klebsiella pneumonia as two gram negative species commonly implicated in sepsis.
However, the 1 pm WtMBL beads performed poorly for capturing bacteria species under the
same conditions. Capture for the bacteria ranged from 35% ± 8% for Klebsiella pneumoniae to
as low as 18% ±7% for Escherichia coli. Based on previous work done in the lab with E. coli
and antibody beads [90], it seemed likely that this was a problem with the bead size and collision
interactions rather than an actual issue with the binding affinity of MBL for the bacteria,
particularly when MBL is known to bind S. aureus and E. coli well in serum [109].
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Figure 2.4 WIMBL Bead Binding in Saline (both 1 pm and 128 nm beads)
(a) Binding of ] pm beads to different species offungi and bacteria: Excellent binding tofingi
but poor binding to the three bacterial species tested (Ec, Sa, Kp). n=3, error bars: SEM (b)
Binding of bacteria with 128 nm beads or a combination of both beads types: Much better
binding of bacteria with 128 nm beads. Adding both bead types in together did not alter the
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binding significantly from that seen with the 128 nm WtMBL beads alone. n=3, error bar: SEM
(c) Binding of E. coli and S. aureus with different concentrations qf 128 nm beads: Able to
capture over 90% of bacteria with higher bead concentrations. n=3, error bar: SEM
To test this hypothesis, the binding experiment with bacteria was repeated using 128 nm
beads (Ademtech) with the same 25 pg WtMBL/mg beads added as was used for making the
1p jm beads (this translated to a higher number of smaller beads with a lower density of MBL on
their surface relative to their 1 pm counterparts). Bacteria capture with these smaller beads was
much better; more than doubling the binding rate for all three species tested (figure 2.4 b).
Further investigations with S aureus and E. coli showed that the binding could be increased to
100% with a higher concentration of 128 nm beads (40 ptg/ml) (figure 2.4 c). See section 2.4 for
a detailed discussion on theoretical factors affecting bead binding.
2.3.1.4 Comparing WtMBL to FcMBL
In blood, the ability of MBL to attach to pathogens and necrotic or mutated human cells
is only a small part of its activity. It is also linked to serine proteases (MASP 1 and MASP2) that
can sense the conformational change in the MBL protein caused by binding, activating the
proteases to recruit the complement cascade, coagulation and phagocytosis to destroy the tagged
cells [106]. These downstream cascades would be detrimental for most of our proposed
diagnostic assays. Therefore, the Wyss Institute created several recombinant versions of MBL
designed to minimize their activation by producing a truncated version of MBL that retained the
CRD binding sites but lacked the binding sites for the serine proteases [124]. I compared the
binding affinity of beads functionalized with the first two versions of the recombinant protein to
beads with WtMBL. I found that these versions of the protein had poorer binding than WtMBL
at all the bead concentrations tested with C. albicans. However, the third recombinant version of
the protein, named FcMBL because it contains two CRD binding pockets attached to the Fc
portion of an antibody (figure 2.5 a-b), actually had slightly higher and more consistent binding
activity than WtMBL coated onto beads when tested. The two MBL beads types were tested with
four different species of fungi, Candida albicans, Candida parapsilosis, Saccharomyces
cerevisiae and Pichia pastoris. The FcMBL bound better to all of them, binding an average of
99% ± 0.3% of the pathogens versus 95% ± 2.5% binding for the WtMBL beads (figure 2.5 d).
These results showed that the activity of the FcMBL on the beads was comparable to or slightly
better than WtMBL and it was much more convenient to work with a protein that could be
produced on demand at the Wyss Institute, therefore, FcMBL conjugated beads were used for
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subsequent testing. Further evaluation of the new protein by other group members showed that it
did indeed have decreased complement and coagulation activity [124].
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Figure 2.5 Recombinant MBL (FcMBL)
(a) Structure of WIMBL showing full polymeric form and composition of each monomer (b)
Recombinant FcMBL produced at the Wyss Institute, with two CRD domains grafted onto Fc
domain derived from a human antibody (c)FcMBL coated on superparamagnetic bead with CRD
heads oriented outward d) Binding offungi with WtMBL and FcMBL 1 Pm beads: Binding with
both the bead types was good but FcMBL beads has slightly a slightly higher binding percentage
than the WtMBL beads for the four of the fungal species tested. n=3, error bar: SEM
2.3.1.5 Dependence of Bead Size, Concentration, MBL Density and Binding Time
The majority of work up to this point had been performed using 1 pm MBL beads
targeted to fungal pathogens, based on extensions with our previous work with antibody beads
and C. albicans [91]. Therefore, a systematic approach to characterize the binding to bacteria
with FcMBL beads was needed. I had already established that 128 nm beads were more effective
for binding the bacteria and wanted to determine the relative importance of other factors on
binding, including bead concentration and FcMBL density on the beads. E. coli was chosen as a
typical bacterium to work with, mainly because S. aureus is known to express Protein A in its
cell wall. This protein allows binds the Fc portion of FcMBL independently of the MBL binding
to the S. aureus, which is beneficial in terms of pathogen capture to this species but does not
37
reflect the actual MBL affinity., Therefore E. coli (the other major bacterial species implicated in
sepsis) would give a much more accurate reflection of MBL binding [127].
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Figure 2.6 Role of bead size, concentration and FcMBL density in binding of E. coli in saline
(a) 128 nm beads: Binding of 128 nm beads was > 90% with more than 15 pg beads/ml sample
and more than 10.1 mM FcMBL/ mA2 on the bead surfaces (b) 1 pm beads: Binding of the 1 pm
beads lower at <60% regardless of bead concentration or MBL density on the bead, never
reaching more than -50%. The green box indicates the MBL concentration typically used to
manufacture the beads (25 mg FcMBL/ mg beads), which appears optimal for both bead types
despite the sixteen fold differences in the surface density on the bead.
The relative effects of different bead concentrations and FcMBL densities with both 1 pm
and 128 nm beads on the binding of the E. coli were compared. As with previous experiments,
the largest factor affecting the binding was the bead size. The 128 nm FcMBL beads were able to
bind over 95% + 1.4% of the E. coli while the best binding with the 1 pm beads was 50% + 1.4%
(figure 2.6 a-b). Bead concentration appeared to have the next greatest effect; bacteria binding
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increased for both bead sizes with increasing bead concentration, plateauing for the 128 nm
beads at 15 pg beads/ml sample while the binding with the 1 pm appeared to saturate at about 25
pg beads/ml sample. The amount of FcMBL coated onto the beads had little impact on the
binding, especially considering the surface density of the FcMBL on the 128 nm beads was much
lower than for the 1 pm because of their much higher surface area per milligram bead. One
milligram of the 1 jim beads contains 5 x 108 beads with a total surface area of 1.6 M2 , while one
milligram of the 128 nm beads contains 4.8x1011 beads with a total surface area of 25 m2 and
both have the same amount of FcMBL per milligram, meaning that the surface concentration of
the MBL on the smaller beads is much lower but the binding is actually better. So given that the
FcMBL surface density of the smaller beads was sixteen times less than for the 1 Pm beads but
the binding was better, it appears that bead size and bead concentration play a larger role than the
FcMBL density for binding in saline. The binding for both bead sizes plateaued at 25 pg
FcMBL/mg (10.1 nanomoles FcMBL/M2 for 128 nm beads, 158.7 nanomoles FcMBL/m 2 for 1
pm beads). Therefore, both beads types were manufactured using 25 jig FcMBL/mg beads for
subsequent experiments.
2.3.2 Binding in Blood
Optimization up to this point had been carried out in saline, but I was primarily interested
in binding pathogens in blood, which is a more difficult fluid to work with (figure 2.7). In terms
of mechanics, blood is a non-Newtonian colloidal suspension of cells, with approximately 45%
of the volume being made up of red blood cells and the remaining volume made up of plasma
[128, 129]. Plasma itself is about six times as viscous as water and it contains high
concentrations of antibodies, complement, glucose, metal ions and trace vitamins; all the things
that need to be delivered or removed throughout the entire body. Blood has a coagulation
cascade in place (mainly composed of plasma proteins and platelets) that will rapidly activate
when the blood stops moving or escapes from a blood vessel. Fibrin monomers then combine to
form a dense polymer network that holds a blood clot together. As a result, blood can transform
from a liquid into a solid in a matter of minutes once removed from the body unless it is treated
with anticoagulants (figure 2.7 b). This process is highly effective at closing cuts in the body to
prevent a patient from bleeding to death but highly inconvenient for most in vitro assays [129].
In addition to these minor complications, one milliliter of blood also contains over a million
white blood cells that will engulf (phagocytose) foreign particles, such as magnetic beads,
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usually in a matter of minutes [63]. All of these factors explain why historically it has been
difficult to directly detect pathogens out of blood. We believed that constructing FcMBL from
proteins normally found in human blood (MBL and IgG) should allow it to bind pathogens but
not mammalian cells, which is not the case for other plant and invertebrate lectins [102, 103].
Removing the MASP binding sites in the recombinant protein should also have the effect of
minimizing activation of clotting and phagocytosis in the blood samples as well [109].
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Figure 2.7 Complexity of Blood
(a) The various components of blood. ,Image reprinted from [130] (b)Coagulation cascade and
different anticoagulants that can inhibit it. Image adapted from [131].
2.3.2.1 Initial Experiments
The initial tests of binding pathogens spiked into human blood were problematic. Tests
with C. albicans indicated less than 19% ± 5.5% binding of the fungi spiked into blood samples
even with 40 jg 1 gm beads/ml sample. Given that MBL evolved to work in blood; I believed
there should be conditions under which the beads should function. Groups using
immunomagnetic beads to isolate circulating tumor cells from blood rely on enriching the
nucleated cells out of blood using a Ficoll density gradients first [73, 87, 88], which would not be
effective for pathogens since their size is on par or smaller than red blood cells. Wills et al. found
that diluting blood was enough to boost the binding so that they could recover circulating
endothelial progenitor cells [75], an approach that I adapted for our assay. Diluting the blood 1:1
with Tris buffered saline with 1% Tween 20 dramatically improved the binding results,
increasing binding of spiked fungi in the blood by as much as 80% (figure 2.8). Gomez et al.
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hypothesized that a small amount of dilution can reduce the hydrodynamic shielding effect in
colloidal suspensions such as blood, improving bead binding [132]. When a sphere moves
through fluid at low Reynolds number (which is the case for the beads), its influence extends out
several radii from its surface, making it interact with nearby objects, which reduces its velocity
[133]. Diluting the blood increased the average gap between adjacent red blood cells from 3 pm
to 4.6 pim, giving the magnetic beads more space to circulate through the volume with less drag
from adjacent cells to slow their movements. I found that further increasing the dilution factor
did not significantly improve the binding, so the minimal possible dilution (1 part saline: 1 part
blood) was used in future experiments. Since then, other researchers at the Wyss have
determined that a 1:4 dilution factor improves the binding further [124], which I used in some
later experiments in chapter 4.
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Figure 2.8 Effect of Dilution on binding of C. albicans with 1 Pm beads in heparinized blood
Diluting the blood 1:1 with saline greatly increases the capture of the fungi. Lysis with Triton X-
100 does not appear helpful in diluted blood and only slightly improved binding in undiluted
blood. n=3, error bar: SEM
Phagocytosis of coated beads was also a major concern (figure 2.9 a). Other members of
the Sepsis group at the Wyss Institute found that using FcMBL rather than WtMBL reduced the
immune activation caused by the MBL on the beads (because the binding sites for the MASP's
had been removed), but it was not enough to completely eliminate phagocytosis [124].
Phagocytosis of the magnetic beads meant that the white blood cells would be collected along
with the magnetically tagged pathogens, which could be a serious problem, particularly for PCR
assays where the leukocyte DNA can inhibit the amplification of the pathogenic DNA [69].
Several groups investigating using superparamagnetic nanoparticles as intravenous MRI
contrast agents have found that the surface coating and bead size play key roles in the bead
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phagocytosis rate in blood [134, 135]. Particles larger than 150 nm in diameter tend to be
phagocytosed quickly, having a half life of 10-15 minutes in blood [136, 137]. Further reduction
bead size was impractical for us since beads smaller than 100 nm generate much less of an
induced force when magnetized, which would make it difficult to recover tagged pathogens. The
128 nm beads were already proving more difficult to recover from blood using conventional
magnetic racks than their larger 1 pm counterparts, so we did not want to reduce bead size any
further. Therefore, a solution to the phagocytosis problem needed to be found. Both the beads
types we employed were large enough to be phagocytosed quickly, so different methods for
preventing or at least slowing phagocytosis of the beads in the blood samples were investigated.
Unlike the groups using these beads for MRI contrast, I could alter the composition of the blood,
so I focused on different sample treatments to reduce the phagocytosis rates. Other members of
the Wyss Institute have been investigating altering the bead size and surface composition. The
simplest method, also employed by other groups working with immunomagnetic beads [73, 75],
is to keep the blood at 4*C, slowing the metabolic machinery driving receptor mediated
phagocytosis. Comparison of phagocytosis rates of 1 im beads in cooled and room temperature
blood samples confirmed that this method effectively reduced the phagocytosis rate for up to 90
minutes so that little or no binding and phagocytosis of the 1 pm beads was observed (figure 2.9
b-c). This gave us enough time to bind and separate the pathogens out of blood with the FcMBL
beads before phagocytosis became problematic.
One percent Triton X-100 can be used to permeabilize and kill white blood cells,
preventing them from engulfing anything. Triton X-100 at this concentration also dissolves the
red blood cell membranes, causing them to lyse. It most likely damages the platelets as well. The
problem with this lysis is that it releases a large amount of pro-coagulant debris, which
surprisingly did not have a significant effect on the binding of C. albicans with the 1 Rm beads
(figure 2.8), but accelerated clot formation. Another destructive method to prevent phagocytosis
is to poison cellular metabolism with a substance such as cyanide or arsenic. However, this was
less attractive due to safety concerns.
In summary, diluting the blood 1:1 with saline buffer and holding the sample at 4*C
during the binding and concentration process was sufficient to increase the binding above the
19% ± 5.5% observed in initial experiments and reduce the phagocytosis rate. The roles of
anticoagulants, bead concentration and binding time in blood were then investigated to further
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improve pathogen binding. The phagocytosis study should be repeated in patient blood at in
various stages of sepsis to determine if the systemic inflammation and subsequent immune
suppression has any major effect of FcMBL bead phagocytosis
a)
I
43
Figure 2.9 Effect of Temperature on phagocytosis
(a) Phagocytosis of 1 pm WtMBL beads (small, darker spheres) in a blood sample with some
phagocytes engulfing more than 10 beads each (b) Isolated beads, indicated with black arrows,
from blood maintained at 4'C during 90 minute incubation showing virtually no phagocytosis of
the beads (c) Isolated beads from blood maintained at 25'C during 90 minute incubation
showing both adhesion (first step of phagocytosis) and phagocytosis of beads. Cells
phagocytosing beads are indicated with a black arrow
2.3.2.2 Anticoagulants
Heparin is a highly negatively charged molecule normally produced in blood vessels to
help prevent coagulation. Purified forms have been widely used in vitro as an anticoagulant in
vacutainers to prevent sample clotting and in vivo for prevention of deep vein thrombosis [138].
Heparin is responsible bringing thrombin in close proximity with its inhibitor, antithrombin III,
preventing activation and clot formation [139]. For these reasons we chose to use it as our
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baseline anticoagulant for all blood-based tests. Donor blood collected into standard 10 ml
sodium heparin vacutainers was stable for over 24 hours at room temperature, suiting our needs.
The fresh donor samples were collected in sodium heparin vacutainers (BD), but it was
not clear if this was enough anticoagulation to allow the FcMBL beads to function optimally. In
blood, I found that resuspending the aggregated beads after magnetic concentration was difficult
due to the deposition of clotted material on the beads, fusing the majority of them together. If the
clotting was initiating during the binding process, it could have been blocking the surface of the
FcMBL beads so that the protein could not access the pathogen surfaces. I experimented with
different anticoagulants to see if this was the case.
Salicylic acid, as the active ingredient in aspirin, is a commonly used platelet inhibitor
that permanently inactivates the COX 1 enzyme in platelets, making it difficult for them to
degranulate and release their pro-coagulant molecules [131]. Adding increasing doses of salicylic
acid to heparinized blood samples did not have any significant effect on the binding. However, it
did prevent clot formation on the beads aggregated by the magnetic field, making it possible to
resuspend beads and tagged pathogens after the field had been removed. One hundred pg/ml of
salicylic acid greatly reduced the amount of clot on the aggregated beads and 1000 pg/ml of
salicylic acid almost completely eliminated it on the 1 pm FcMBL beads (figure 2.10 a-d).
These results indicated that the clot formation was not playing a major role in blocking the
pathogen binding in these tests but only making it difficult to resuspend the magnetically
aggregated beads and pathogens.
The calcium levels of blood are tightly regulated to stay around 2.1- 2.8 mM in the body
because calcium is required for muscle contraction, nerve conduction, but it is also a key
cofactor for several of the enzymes in the coagulation cascade [140]. Many common
anticoagulants, such as ethylenediaminetetraacetic acid (EDTA), work by depleting blood
calcium levels to slow sample clotting [141]. EDTA works by chelating calcium (and other metal
ions), which is a required cofactor for several of the enzymes in the coagulation cascade.
Therefore, removing ionic calcium from the plasma can effectively slow clot formation and give
clinicians time to perform tests on the blood. However, the calcium depletion is a problem for
MBL as well, since it also requires calcium as a cofactor to stabilize the CRD binding pocket. I
had determined in saline that little or no binding would occur without calcium in the buffer
(figure 2.3). However, many clinical samples are treated with EDTA, so we needed to see if it
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was possible to bind pathogens in them. To accomplish this, blood was recalcified immediately
before adding the FcMBL beads and mixing the sample for binding. This provided
approximately 40 minutes to bind and concentrate the pathogens out of the sample before
clotting began in earnest. Using this approach I found no significant difference in binding
between the recalcified blood and heparinized blood except when no calcium was added, in
which case binding in EDTA blood was lower than in the heparin samples (figure 2.10 d).
Adding a therapeutic dose of heparin before recalcifying the blood prevented reactivating the
coagulation cascade and made the blood stable over several hours [124].
Heparin was preferred for these assays due to its simplicity, however, but it was possible
to get comparable binding in EDTA treated blood samples with the correct treatment, giving the
FcMBL beads much more flexibility when working with clinical samples.
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Figure 2.10 Effect of Salicylic Acid on Coagulation and binding in blood
(a) Aggregated 1 um beads with no Salicylic acid added, faint outlines offibrin clots can be seen
holding the clumps of beads together (b) Aggregated 1 pm beads from blood sample treated with
100 pg/ml salicylic acid, much less fibrin formation and some free beads visible (c) Aggregated
1 um beads from a blood sample with 1,000 ug/ml Salicylic acid added, virtually no fibrin clots
visible, mainly free beads. Any aggregates are composed of less than 5 beads (d) Effect of
Salicylic Acid at 1,000 pg/ml on the binding of C. albicans in undiluted blood : no major effect
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on the binding offungi in blood in lysed (1% Triton X-100) or unlysed blood. n=3, error bar:
SEM (e) Binding of C. albicans with 1 pm FcMBL beads in diluted blood in Heparin vs. EDTA
treated blood (diluted 1:1 with buffer): EDTA blood with no calcium added has lower binding
than heparinized blood although still higher than expected. With calcium added to the samples,
the binding performance of both was comparable. n=4, error bar: SEM
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Figure 2.11 Binding and separation of magnetically tagged fungi and bacteria from diluted
blood
(a) Binding of C. albicans with 1 um beads with different mixing times (b) Binding and
separation of C. albicans from diluted blood with 33. 3pg 1 pm beads/ml sample: binding and
magnetic pulldown of C. albicans with the larger beads looks good n=2 error bar: SEM (c)
Binding and separation of C. albicans from diluted blood with 50 pg 128 nm beads/mi sample:
Magnetic separation of fungi with the smaller beads is more variable, taking longer but
saturating after about 7 minutes in the magnetic rack n=2, error bar: SEM (d) Check of binding
and separation of S. aureus with 50 pg 128 nm beads/ml sample in diluted blood: Bacteria were
pre-tagged with beads before being added to diluted blood (separation) and bacteria were
mixed with beads for different amounts of time (binding and separation)in diluted blood. Not
able to pull out magnetically tagged bacteria with the DynaMag 2 rack. Poor recovery of pre-
bound bacteria indicates that the DynaMag 2 rack is failing to pull out the 128 nm beads due to
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their having a smaller induced magnetic dipole. rack n=3 error bar: SEM (e) Check of binding
and separation of S. aureus with 50 pg 128 nm beads/ml sample in plasma: Bacteria were pre-
tagged with beads before being added to diluted plasma (separation) and bacteria were mixed
with beads for different amounts of time (binding and separation). Much better separation out of
plasma, DynaMag 2 rack works alright when blood cells are not present. n=3 error bar: SEM
2.3.2.lReevaluating Bead Concentration, Bead Size and Binding Tne
Reevaluation of bead binding parameters was important at this stage due to the
complexity of blood as a multi-component fluid. Its higher viscosity and colloidal nature slows
movement of beads and pathogens, both during the binding and separation phases. For these
reasons, I suspected that many of the guidelines for good binding found previously in buffer
would have to be reevaluated. A systematic investigation into the optimal binding time,
separation time, bead size and bead concentration for binding in the diluted blood samples
should increase the binding further.
For C. albicans with 1 pm FcMBL beads at 10 pg beads/ml in blood, I found the
binding plateaued at 91% ± 1.2% after approximately 12 minutes of mixing time in an inverting
shaker (figure 2.11 a). For S. aureus with 128 nm beads at 50 pg beads/ml, I found the binding
in blood saturated after 15 minutes of mixing time at 18.4% ± 7% (figure 2.11 d-e). The poor
separation of S. aureus in blood indicated that the commercial magnetic rack used to recover
them was not sufficiently powerful enough to pull out the smaller 128 nm beads. Both binding
and separation of the bacteria worked fine in plasma (figure 2.11 e), so it appears that the poor
depletion is mainly caused by the cellular fraction of blood. The most likely explanation is that
the red blood cells impede the motion of the magnetic beads and tagged bacteria. From these
experiments, it was concluded that 20 minutes of mixing time was sufficient for the binding to
reach completion in blood for both fungi and bacteria, which was double the 10 minute time
employed in saline.
Binding of bacteria in diluted blood produced variable results, prompting examination of
the pitfalls of using the smaller beads (figure 2.12).The 128 nm beads were more difficult to use
in blood because they are much more difficult to pull out onto the magnetic than the 1 tm beads.
This is due to their volume being 1/4 70 th that of the 1 pm beads. The volume of the beads
controls the number of magnetic nanoparticles crystals inside, which determines the magnetic
force on the bead when it is placed in the magnetic rack, so the 128 nm beads have a smaller net
magnetic force on them than the 1 pm beads [142]. Difficulty in pulling out the beads and tagged
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pathogens affected the results of the depletion assay because it was also picking up magnetically
tagged pathogens that had not finished being pulled out of the blood.
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Figure 2.12 Binding of Bacteria in blood with 1pm and/or128 nm beads
Twenty five micrograms of each bead type per ml diluted blood added. Binding to the bacteria is
variable, possibly due to poor magnetic separation with the 128 nm beads. Adding both bead
types together seems to reduce the variability of the binding to a small degree. n=3, error bar:
SEM
For fungi, it made a great deal more sense to use the larger 1 pm beads, since we knew
they bound well to the larger pathogens and they created a large force when magnetized by the
DynaMag 2 rack (Invitrogen), although magnetic separation of the fungi with 128 nm beads was
also satisfactory, most likely due to the larger surface area of the fungi allowing up to fourteen
thousand 128 nm beads to attach. This would give force comparable to about thirty 1 pm beads.
Considering we can pack up to two hundred thirty 1 pm beads on a typical C. albicans cell, it
made much more sense, in terms of magnetic separation, to use them. This difference may also
explain why the separation of the fungi was more variable with the smaller beads, since the net
force on the pathogens most likely lower (figure 2.11 b-c). The 128 nm beads bound better to
the bacteria but were much more difficult to pull out of blood. Even when the 128 nm beads
were prebound to bacteria before adding them into the diluted blood sample, only able to recover
40% of them were recovered (figure 2.11 d) and the separation was much more variable than
with the 1 pm beads and fungi. It appears that a lot of the problem was the cell-based component
of blood, since I ran the same test in plasma and was not only able to separate out only 95% of
the prebound pathogens, but also bind and separate up to 90% of S. aureus spiked the plasma
sample with 50 pg beads/ml (figure 2.11 e). Based on the hypothesis that the DynaMag 2 rack
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was poorly optimized for recovering nanometer scale beads from blood, I developed two new
separation strategies to recover bound bacteria from blood in Chapter 4 which boosted bacteria
separation up to over 85% out of diluted blood.
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Figure 2.13 Binding of C. albicans in diluted and undiluted blood with different concentrations
of ] pm FcMBL beads
Binding in diluted blood is better, although relatively high capture rates in undiluted blood are
possible at high enough bead concentration
The binding of C. albicans in both diluted and undiluted blood was tested with a range of
different bead concentrations and showed that I could obtain an average of 86% ±14% fungi
capture in diluted blood with 25 pg beads/ml sample in diluted blood and up to 75% ±20%
binding in undiluted blood (figure 2.13). The standard deviation between different donors was
relatively high (over 20% in some cases). Other members of the sepsis group at the Wyss
Institute have been studying causes of this inter-donor variability. The impact of different
fractions of on binding was examined and revealed the most consistent factor that decreased the
binding was the red blood cells. Adding red blood cells to a saline sample lowered the capture
rate of the pathogen more than plasma, serum or platelets from blood. In a small fraction of the
donors tested, there were components in their serum that inhibited binding as well, which we
hypothesize was IgG antibodies and other endogenous opsonization proteins against the
pathogens which blocked the binding sites for our FcMBL beads. However, no correlation
between endogenous MBL levels in our donors and C. albicans binding in diluted blood was
found.
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Since these investigations were carried out, other members of the Wyss Institute have
developed binding and separation systems that can recover over 80% of S. aureus and E. coli
from blood [143]. Working with these initial guidelines, Mark Cartwright, Martin Rottman,
Nazita Gamini and others have developed a high throughput method to test FcMBL bead binding
to a wide range of pathogens (figure 2.14) [124]. From their investigations, they have found that
binding in EDTA blood could be improved further by diluting 1:4 with TBS-Tween 20 with 5
mM calcium and treating it with ten mM of glucose and 0.8 mg heparin per ml (JT Backer Inc.)
[124]. I made use of these improvements to help characterize new methods for separation of
bound bacteria out of blood in chapter 4.
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Testing of FcMBL bead capture of bacterial species performed by other members of the Wyss
Institute. This expanded study shows that FcMBL beads can bind to many pathogenic bacteria,
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although they have the same difficulty with encapsulated pathogens that serum MBL does. Image
adapted from [124]
2.4 Bead Binding Theory
The binding of pathogens with the magnetic beads is affected by several factors, including
diffusion, convection and the binding reaction itself. The binding reaction is dependent on both
the collision rate between the beads and the target pathogens and the actual binding chemistry of
MBL to the pathogen. For a diagnostic system where the concentration of pathogens (C) is
unknown, certain parameters can be used to improve the binding. The first is bead concentration
(Cb) added to the sample. For binding rare pathogens in a timely manner, a large excess of beads
is required to maximize the odds of the beads coming in contact with the pathogens [144]. To a
small extent, diffusion can be controlled by changing the size of the beads. For increasingly
small beads, the importance of diffusion in the binding rate becomes increasingly important as
their diffusion coefficient increases [84]. The fluid convection that is responsible for dispersing
the beads throughout the sample can be controlled by the mixing parameters employed in the
system.
The actual collision rate and the binding rate given pathogen-bead contact are the most
complex parts of the problem, dependent on both collision theory and the binding chemistry of
FcMBL itself. The collision rate between the beads and pathogens (Rcb) is a function of their
concentrations, their relative velocity (veb) and their radii (rc for the pathogens and rb for the
beads) [84]:
Rcb - Crre + rb) 2 CbCVcb
(2.3)
The actual binding rate is typically lower than the collision rate since not every contact event
results in binding [86]. The probability of binding given contact depends on the chemistry of the
MBL, the constituents in of the fluid (like calcium), the shear rate between the pathogen and the
bead and the surface density of antigens on the surface of the pathogen [145]. This subject is
highly complex and warrants a detailed investigation of its own, particularly since relatively little
quantitative data on the density of mannose and fucose residues on the surfaces of different
pathogens is available. For these analyses, I will focus primarily on the mechanics of binding
interaction. Other members of the sepsis group at the Wyss are working to optimize the binding
chemistry (such as adding glucose to lessen non-specific FcMBL binding [124]).
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The collision rate is proportional to the mean free path of the beads in the fluid, which is
why the radii of each and their concentrations must factor into the analysis. The relative velocity
between the beads and pathogen at the time of collision depends both of the difference in
velocities between the streamlines containing the bead and the pathogen and the diffusion
velocity of both species across different streamlines [84, 146]. The Peclet (Pe) number gives an
estimate of the relative importance of convection over diffusion for both beads sizes and not
surprisingly diffusion is more than ten times as important for the smaller 128 nm beads [125].
ru
Pe = -D
(2.4)
Where r is the characteristic length of the system (assumed to be on the order the bead diameter
here), u is the characteristic velocity (assumed identical for both bead types and on the order of 1
cm/s in the (given the rotation rate of the inverting mixer), and D is the diffusivity of each bead
type (calculated with equation 2.1).
To try and understand why the 1 im beads did not work nearly as well for bacteria, a
closer examination was taken of the binding kinetics and the maximum number of beads that can
attach to each pathogen type. The relative velocity induced by diffusion (vdiff) is [84]:
4(Dc + DO)
Vdiff 
- (r(C +rb)
(2.5)
This full form of the equation must be used when the bead and pathogen are of similar size
(assumed to be the case for the 1 tm beads binding to 1 pm bacteria) because the relative
Brownian motion of each is of similar importance and must be taken into account. However, if
the bead is much smaller than the pathogen (assumed to be the case for the 1 pm beads binding
to 10 pm fungi and the 128 nm beads binding to the 1. pm bacteria) , the relation simplifies to
4Db
Vdiff =
rc
(2.6)
because diffusivity of the smaller bead dominates the motion and the larger pathogen can be
approximated as stationary. This results in faster diffusion of the bead to the pathogen surface,
increasing the binding rate. Increasing the mixing speed can increase the convective relative
velocity, but it also increases the shear rate between the bead and pathogen, which is believed to
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reduce the probability of binding given contact because there is not sufficient time for avidity
binding to occur before the bond is stressed; only a few CRD's attach before the bead is torqued
by the fluidic shear. If the bead diffuses to the surface of the pathogen, there will be more time
for many CRD's to attach, creating a strong bond through avidity that is unlikely to be broken by
shear. The larger beads on the surface of a bacteria would also be subject to more shear than the
smaller beads, making them more likely to be ripped off while beads much smaller than the
pathogen will be more protected by the boundary layer flow on the surface of the pathogen and
should be submitted to lower shear rates, making them more likely to stay in place [133].
A second reason that can explain why the 1 pm beads do not effectively bind to bacteria
is the maximum number of beads that can attach to the pathogen. The surface density of spheres
on a planar surface (p2d) is [84]:
Ir
P2d = -- 90.7%V1-2
(2.7)
If the bead is much smaller than the pathogen, the pathogen surface can be treated as roughly
planar, so the total number of beads that can attach to the surface (Nmax) is [84]
/ 2
N.=4pI -Nmax = 
4 P~dC _)2
rb
(2.8)
Using this relation, approximately two hundred thirty 1 pm beads can attach to one fungal cell
and about two hundred twenty 128 nm beads can attach to one bacteria; very similar for both of
them. This approximation is not valid for 1 pm beads, where trying to pack beads onto the
surface of something with nearly equal size is much more complicated. The larger beads will
wind up having to competing with each other if enough bind to begin covering the pathogen
surface.
Judging from these calculations and empirical observations with the different bead sizes,
the binding of pathogens with beads appears more effective if the beads are much smaller than
the pathogen (at least 1/ 10th the size). This allows the relative diffusive velocity to increase
slightly because the movement of the pathogen is no longer significant. The smaller beads should
also be more sheltered from fluidic shear during the initial binding instant when avidity is being
established and more of them can be easily packed onto the surface of the pathogen. Reinforcing
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this concept is that the 128 nm beads can effectively bind to the larger fungi as well, packing
roughly up to 14,000 beads onto the surface. The main disadvantage of this approach is that the
smaller beads exert a much smaller magnetic pull on the pathogen, making it more difficult to
pull them out in a given magnetic field, a problem that I address in detail in later chapters.
2.5 Discussion
Our objective was to create a single set of magnetic beads that could bind a wide range of
pathogens in blood by coating the beads with a general opsonin derived from the human
primitive immune system called MBL. In serum this protein is capable of binding to a wide
range of bacteria and fungi and I have shown that this magnetic beads coated with this protein
can bind a wade range of pathogens in saline and blood [109] .
I decided to move away from using the flow cytometer for quantification and employ plate
based quantification instead for several reasons. The first was that the cytometer worked fine for
picking up the larger ftngal cells used for most my initial evaluations, but it had much more
difficulty detecting the fluorescence signature of an individual bacterium in the millisecond it
was illuminated. The other reason was that flow cytometry had difficulty detecting less than
1,000 cells per ml, and that number went up to 10,000 cfu/ml if I was trying to detect pathogens
in blood samples (due to the increased complexity of the sample). Microbiological plating could
operate at pathogen concentrations much closer to the physiological range in sepsis (1000 to 100
cfu/ml) and was not affected by the complexity of the sample. With proper controls and
technique, we found that plating was an accurate way to assess pathogen concentration in a
sample. It had the added advantage that all the analysis could be done in the BL2 facility, rather
than having to risk bringing blood and pathogen samples out of containment to the flow
cytometer at the Wyss Institute core facility. In addition to the plating depletion assay, several
other group members at the Wyss Institute have recently developed ELISA and Bactiter Glo
assays to quantify FcMBL binding to pathogens and the viability of the captured pathogens
[124].
I chose to use the depletion assay to measure binding because we had determined that the
MBL beads can cause pathogens to aggregate, so that what looked like a single colony during
plate analysis may in fact have originally contained several bacteria welded together by the
beads. The unbound bacteria remaining in the sample fluid did not normally aggregate, so
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comparing the positive control to the unbound pathogens proved a more reliable way to quantify
the binding.
The development of a single set of magnetic beads that can bind to many pathogens,
including S. aureus, E. coli and C. albicans (three important species in sepsis), but not
mammalian cells has huge implications for the diagnosis of sepsis because it offers a novel
method to bind and separate unknown pathogenic cells out of blood. In our previous work with
magnetic beads in blood, we could only pick up one known species at a time [91]. Most other
work immunomagnetic beads in blood has focused on capturing nucleated cells such as tumor or
progenitor cells, which allows them to use size-exclusion centrifugation [73, 75, 87, 88]. The
similar size of pathogens to red blood cells means that this approach is not viable for binding
pathogens, but I have shown that we can obtain good binding without this sample preparation
technique. MBL has the advantage relative to other plant or invertebrate lectins in that it evolved
to function in blood and typically does not bind to human cells. Plant and invertebrate lectins
also have the ability to bind a wide range of bacteria, but they bind to blood cells as well,
severely limiting their utility in human samples [102, 103, 126] while MBL has no such problem.
Magnetic bead and rack systems are robust, inexpensive and easy to use. The ability to bind and
concentrate pathogens directly out of blood makes direct detection of an infection possible,
without the need for a time consuming and unreliable culture step first [27]. These two abilities
mean that these general opsonin beads could form the basis of a rapid sepsis diagnostic
technology that would not require an expensive, culture-based central laboratory to operate.
Other members of the Wyss Institute are also actively investigating the use of these beads in a
dialysis-like therapeutic system to continuously remove pathogens from the blood of septic
patients to help stop the spread of the infection. Blood is arguably one of the most complex fluids
in the world [147], so the fact that these MBL beads can operate in it suggests that they may
function in a wide range of other complex samples, so they may have applications in the testing
food for bacterial contamination as well.
For working with blood, I was looking for the simplest effective sample treatment methods
because we were developing these beads to be used a general method to recover pathogens from
blood for a wide range of applications, both diagnostic to therapeutic. Dilution, cooling and
heparin were sufficient to give good binding without significantly increasing the sample volume
or damaging the pathogens. Radiation or chemical treatments could have also inactivated the
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phagocytes in the sample, but this would then interfere with potential downstream PCR or AST
testing by degrading the pathogen DNA and viability [21]. Dilution of blood 1:1 with saline
greatly improved pathogen binding, boosting it as much as 80% in the blood of some donors and
addition of extra anticoagulants (EDTA, salicylic acid), had no significant effect on the binding.
These treatments were typically withheld unless they were needed for something after bead
capture (like using the salicylic acid treatment to make the beads easier to resuspend after
concentration). Work is ongoing to improve binding in blood further using various blood
treatments (anticoagulants, sugars), bead size, bead concentration and bead surface chemistry in
the sepsis group at the Wyss Institute, improving on the groundwork laid here.
Despite these relatively simple treatments, we were able to show that FcMBL beads can
effectively bind more than 20 different pathogen species in both saline and blood, including
gram positive and negative bacteria and fungi. The recombinant form of MBL (FcMBL)
conjugated to magnetic beads appeared to be able to reproduce the binding abilities of the native
serum protein. My experimental measurements found that bead size and bead concentration were
the two biggest factors affecting binding in saline. Collision theory confirmed that binding to
pathogens is most effective when there is a large excess of magnetic beads that are much smaller
-A 7] E E Z] Ei 1E] E 1 I [84], roughly 1 / 1 0 th the diameter or less. For this reason,
we chose to use 1 im beads to bind the larger fungi and 128 nm beads to bind to the smaller
bacteria. Blood is a much more complex fluid, so I had to increase the bead concentration,
binding time and separation time relative to that used in saline in order to achieve a similar
amount of fungi binding. I also found that the disadvantage of the smaller 128 nm beads is that
the bacteria tagged with them are much more difficult to magnetically separate of blood with a
commercial magnetic rack, even though the actual binding to bacteria seemed fine. This led me
to develop several strategies to boost the magnetic field that boosted separation of magnetically
tagged bacteria to more than 85% (see chapter 4). These experiments should be repeated in the
blood from septic patients when available to determine immune up regulation or suppression
(depending on the sage of sepsis) significantly alters the behavior we have observed in blood
from healthy donors.
I have laid out the groundwork for using the FcMBL beads in blood which other members of
the sepsis group at the Wyss Institute are actively expanding to further maximize pathogen
binding and determine the full range of pathogen species and strains that these beads can be used
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to capture. To date they have confirmed that FcMBL beads can bind over twenty different
pathogens in blood, including MRSA, VRE and Salmonella species [124].
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Chapter 3 Optical Detection of Fungi
3.1 Introduction
Fungemia is becoming increasingly problematic in intensive care units (ICU). It was once
a rare infection but now represents 6-11% of sepsis cases thanks to an increasing number of
immunocompromised patients who have difficulty clearing fungal infections, usually a Candida
species [19]. Patients have a higher probability of survival if effective therapy is started in the
first 48 hours, but it usually takes 3-7 days to detect fungi with traditional blood culture and AST
techniques [19]. We have shown that magnetic beads coated with recombinant mannose binding
lectin (FcMBL), can bind to a wide range of pathogen species in blood, particularly fungi. Here,
I have used these beads as the basis of a diagnostic system to rapidly detect the presence of fungi
in blood. Concentrating fungi out of blood using magnetic beads is a relatively simple matter,
but visualizing them for rapid, optical detection is much more difficult due to them being buried
among the excess beads. The one of the major limitations for rapid detection was that the large
excess of opaque, magnetic beads required for optimal binding obscured the fungi we were
trying to optically detect. To overcome the difficulty of visualizing rare pathogens captured with
magnetic beads, I have developed a microdevice that can efficiently concentrate magnetically
tagged pathogens from a blood sample for optical detection by balancing the fluidic shear and
magnetic field so that the beads and bound pathogens from the sample are spread into a thin
layer suitable for automated detection with an epifluorescence microscope. Using this system, I
have detected the presence of C albicans in fresh human blood samples at concentrations down
to 1 fungus/ml in less than three hours.
3.2 Materials and Methods
3.2.1 Microdevice Fabrication
All devices and prototypes were made from polydimethylsiloxane (PDMS), also called
Sylgard 184 (Dow Coming). The base and curing agent were mixed in a 10:1 ratio by weight
according to the manufacturer's instructions. Device fabrication employed standard
microfabrication techniques [148], but we employed a variety of different methods to produce
the molds from which PDMS devices were cast.
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The molds for the early devices (before micropatterning was introduced) were fabricated
using a rapid prototyping method developed by Chong Yung in the Ingber lab. The layout of the
device was created using Corel Draw and then a CE5000-60 cutter-plotter (Graphtec) cut the
pattern of the channels out of 80 gm thick mirror chrome Mylar (Supplies Unlimited Inc,
Wakefield, MA). The excess Mylar could then be picked out of the design using the tip of a
scalpel blade and the sticker of the channels could then be moved into the bottom of a flat Petri
dish using transfer tape (Clear Choice, South Planinfield, NJ). Multilayer patterns could be
constructed by stacking layers of the Mylar stickers on top of each other, allowing us to create
devices with heights of 80 pm, 160 pm, 240 gm and so on. The cutter plotter could not reliably
create patterns smaller than 500 pm, so this technique was largely used to create millimeter scale
features. By using this approach, a sketch could become a useable PDMS device in less than one
day.
a) Cast Epoxy
b) Remove Mold
c) Cast PDMS
d) Bond to glass
Figure 3. JFabrication of microdevice mold
(a) A sacrificial master device (made of Mylar (grey) and micropatterned PDMS (blue) is
duplicated using casting epoxy (yellow/orange) (b) After the casting epoxy has set, the sacrificial
master is removed and the mold prepared for use (c) uncured PDMS is poured into the mold and
a glass slide laid across the top to create a microdevice with a defined thickness (d) The
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microdevice with a combination of millimeter scale fluid channels and micron scale patterns on
the channel ceiling is removed from the mold and bonded to a glass slide, ready for use.
To combine millimeter scale channels with micron scale features, I developed a method to
combine the large scale Mylar-patterned channels with micropatterned features created using
standard SU-8 photolithography methods (figure 3.1 a-d). To do so, I combined Mylar channels
created with the cutter plotter with micropatterned PDMS to make a sacrificial master device that
was then cast in epoxy to produce the final mold. I designed various types of micropatterned
features for the magnetic beads to settle into using AutoCAD and Output City (Boston, MA)
produced a transparency mask that was used to cast several SU-8 wafers with various feature
heights (10, 20, 40, 80 pm) onto silicon wafers at the Harvard CNS facility. To fabricate the
micropatterned PDMS that would form the ceiling of the microdevice, I placed 280 pm spacers
on edges of the wafer to define the thickness of the PDMS. Then a glass plate was clamped
across them. Once cured, I removed the PDMS from the wafer and attached it to several stacked
Mylar stickers that formed the shape of the channel to make a sacrificial master device (figure
3.1 a). This was what the final device would look like. A negative of this device was cast with
EasyCast Clear Casting Epoxy (Castin'Craft), after which the sacrificial master was peeled out of
the epoxy and the epoxy was then used to cast PDMS devices of a defined height by clamping
down a glass slide across the top of the epoxy while curing (figure 3.1 b-c).
Once the PDMS device had been removed from the epoxy mold, I punched inlet and outlet
ports in the device using a 3 mm biopsy punch. Next it and a glass coverslip were treated with
oxygen plasma for thirty seconds and sealed together. Tygon tubing (1/8" OD 1/16" ID, Saint-
Gobain Performance Plastics) was then inserted into the ports in the device and glued in place
using 9-1363 Industrial Assembly Adhesive (Dow-Coming), after which the devices were ready
for use.
The final prototype consisted of a single long channel (3mm wide, 35 mm long, 280 pim
high) with a repeating array of wells (50 ptm in diameter, 20 im deep) micropatterned into the
ceiling of the middle 25-mm section of the channel. In each row, the circles were spaced 100 pm
apart with each subsequent row 50 pim below the previous row and shifted 50 pm relative to it.
The ceiling of the channel separating the MFC from the liquid in the channel was made as thin as
possible (300 pm thick) to minimize the dissipation of the magnetic field.
3.2.2 Testing Early Prototypes
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The early version of the diagnostic device was constructed using the Mylar cutter plotter to
create the molds (section 3.2.1). It contained a low shear capture chamber 4 mm wide by 20 mm
long by 240 tm high over which were positioned five stacked neodymium magnets (2"x 1/4"x
1/8," K&J magnetic) as shown (figure 3.2). Concentration and detection was tested in this
device using either 10 ml of saline or packed red blood cells obtained from the Children's
Hospital Blood Bank, diluted to 40% hematocrit with saline. Different concentrations of C.
albicans were added along with 25 iM Calcofluor to stain their cell walls and 50 pg 1 im
WtMBL beads/ml sample. The beads were mixed for 30 minutes and then run through the device
at 10 ml/hour, followed by a 3 ml saline wash to flush out the blood out of device for imaging.
For imaging, the magnet was removed from the top of the device and used to manually
manipulate the beads in the capture chamber to spread them out on the bottom of the device (the
glass slide). The device was then scanned with an epifluorescence microscope looking for
fluorescent yeast cells, using their fluorescence, size and morphology to differentiate them from
background.
Low Shear Chamber
c)
d) Cross Section of Device
Magnets
Fluid
Flow
. .
4 mm
Figure 3.2 Initial Diagnostic Prototype
(a) Blood with magnetically bound pathogens enters the inlet port on the left, flows through the
device where the magnets pull out magnetically tagged pathogens in a low shear chamber and
the blood is then removed through the outlet. (b) Device with the magnet removed (c) Schematic
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of device showing location of the low shear chamber (d) Cross-section of low shear chamber:
beads and tagged pathogens enter the chamber and are pulled up the ceiling of the chamber
where they are retained
3.2.3 Mass Balance Study
To determine where the pathogens were going in the device, I performed a set of mass
balance experiments to check for non-specific adhesion, pathogen capture and optical detection
of pathogens. This testing was done using 850 cell aliquots of GFP transfected C. albicans,
donated by Brown et al [123], metered out using a FACS Aria cytometer (BD) to obtain very
accurate pathogen counts in each aliquot.
a) Thaw cell b) Dilute in 10 c) Add MBL
aliquot from ml saline beads, let bind
freezer
d) Run sample solution
through device
Objective: Determine if beads are not
binding to cells and/or failing to remove
them from solution
f) Concentrate
down to 100 g
) Collect Outlet g) Count fungi in 10 pl ofFrom Device outlet concentrate and
those caught in device
Figure 3.3 Initial Diagnostic Prototype
(a) 850 fungi aliquot is removed form cyrostorage (b) Fungi are diluted in 10 ml of saline (c)
WtMBL beads are added and given time to bind (d) fluid sample is run through the device and
the number of detected pathogens determined by scanning over the low shear chamber using
epifluorescence microscope. The positive control sample bypasses this step (e) Outlet fluid from
the device is collected (f) Outlet fluid is centrifuged and aspirated down to 100 ul (g) The
number of pathogens not captured in the device is determined using hemocytometer to count
number of fungi in the outlet fluid and comparing that to the positive control. Non-specific
adhesion to the device surfaces was assessed using this same system except that WtMBL beads
were not added, so any fungi binding was due to attachment to the surfaces. Countess chip image
reprinted from [149].
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These tests were performed in saline. To determine the concentration in samples after
testing, each sample was spun for 10 minutes at maximum speed in the centrifuge and then the
liquid was aspirated so that only 100 ptl remained, in which all the fungi were resuspended and
their concentration determined by manually counting the number of fluorescent fungi in 10 p1 of
that fluid using a hemocytometer chip (from the Countess Machine, Invitrogen). This method
allowed us to accurately quantify a physiologically relevant number of pathogens in the system
for these tests.
I ran the entire system without magnetic beads to check for adhesion of the pathogens to the
surfaces of the tubing or device and compared the count to control samples not passed through
the device. For evaluating pathogen capture vs. detection, I ran the system with magnetic beads
this time (40 pg 1 pm WtMBL beads/ml). I then used a microscope to scan over the device and
determine the number of pathogens optically detected and evaluated the number of pathogens not
captured in the device by checking the outlet fluid for fungi. Both of these counts were compared
to a positive control sample that was not passed through the device to determine what fraction of
the fungi were detected and what fraction were lost in the waste (figure 3.3).
3.2.4 Magnetic Flux Concentration Characterization
I evaluated different geometries for the MFC with Dan Leslie and Karel Domansky using
finite element modeling in COMSOL to analyze the magnitude of the magnetic gradient created
by each magnet and Permalloy configuration. The magnetic flux concentrator was designed in
SolidWorks and CNC-machined from EFI alloy 79 (Ed Fagan, Inc.) The alloy has maximum
relative permeability of 230,000 and saturation induction of 8700 Gausses. The MFC was
employed to alter the field generated by a 3/4" neodymium cube magnet (K&J Magnetics) and a
non-magnetic polysulfone holder was used to keep the MFC and the magnet correctly positioned
relative to each other. The MFC is composed a of single bar of the EFI permalloy 5 mm wide,
1.55 mm thick and 25 mm long. The front end is tapered to a wedge in order to decrease the
initial magnetic field gradient spike produced by the magnet. The remaining area of the MFC has
400 pm deep and wide grooves with 800 pm center-to-center spacing. These grooves create
places where the magnetic field lines diverge outwards periodically, resulting in the high
magnetic field gradient zones required for bead captured. Finite element modeling results were
validated by securing a Hall magnetic probe to a motorized xyz positioning system and scanning
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it 500 ptm above the MFC surface to measure the magnetic field produced by the MFC and
magnet.
3.2.5 Bead Isolation
The efficiency of magnetic bead isolation with the MFC and microfluidic flow cell was
tested by running a 10 ml water sample through the device containing 5 pLg 1 pm beads/ml. The
sample solution was agitated with a thermomixer (Eppendorf) to prevent bead settling while a
peristaltic pump (Ismatec) pulled liquid through the device at 10 ml/hr. Photographs of the bead
distribution in the micropatterned device were obtained on a trans-illumination microscope after
the magnet and MFC had been removed and the bead concentration in the outlet was analyzed
with a BD Fortessa flow cytometer to determine the fraction of magnetic beads removed by the
device.
3.2.6 Running the Diagnostic Device
The efficiency of the combined MFC and microfluidic device was determined by detecting
850 GFP positive C. albicans (counted out using FACS) added to either 10 ml of saline (TBS-
Tween 20 with 5 mM calcium) or in 5ml of human blood diluted with 5 ml of TBS-Tween
(maintained at 4"C during assay). For experiments using pre-bound fungi, the fungi were
resuspended in 1 ml of TBS-Tween 20 with 5 mM calcium chloride and 50 ptg FcMBL beads
then mixed for 20 minutes before adding to 5 ml of blood and 4 ml of TBS-Tween to create the
10 ml sample. For direct capture in blood, we added the fungi and beads directly to a mix of 5ml
of blood and 5 ml of TBS-Tween 20, without any pre-binding time, and gave 20 minutes of
mixing to bind the pathogens in the diluted blood.
Calcofluor white (25 pM) was added to the sample to stain the fungal cell walls. Blood was
collected from healthy human volunteers into heparin vacutainers (BD). The fungi were bound
using 1 pg of 1 pm beads/pl in saline or 5 pg of 1 ptm beads/pi in blood. After binding the
sample was placed in thermomixer (Eppendorf) and pulled through the device at 10 ml/hr using a
syringe pump (Harvard Apparatus) equipped with a 20 ml syringe (figure 3.4). After the 10 ml
sample had been run, a 3 ml wash for saline. For blood, I added a 2 ml wash (for blood) of TBS-
Tween 20, followed by a 1 ml wash containing 1% Triton X-100 and a final 2 ml TBS-Tween 20
wash through the device. The Triton X-100 lysed any residual red blood cells trapped in the
device. Detection efficiency was determined by manually scanning over the device at 200x with
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an epifluorescence microscope (Leica) looking for cells with an overlapping calcofluor and GFP
signature.
Tests in saline with several different bead concentrations were done to study the relation
between pathogen detection and bead concentration. Samples were run with 560 pm high
channel without micropatterning (performed before bead isolation studies to optimize channel
design) with bead concentrations ranging from 1 to 2.5 pg 1 pm WtMBL beads/ ml in 10 ml of
calcium buffer with one 850 C. albicans aliquot added.
a)
Pathogen Binding
Inverting Mixer
C) d)
b)
Microdevice and
MFC
Syringe Pump
10 m/hr
Thermomixer
650 RPM, 40C
Figure 3.4 Experimental Layout of Optical Diagnostic System
(a) MBL beads were added to the samples and mixed for 20 minutes in an inverting Hula Mixer
(Invitrogen). Hula Mixer image reprinted from [150] (b) Then the fluid sample is placed in the
thermomixer, which agitates it to keep the beads and pathogens suspended and cools the sample
to minimize phagocytosis. A sip tube takes fluid from the sample tube and pulls it through the
microdevice with the magnet and MFC in place (c) where the magnetic beads and magnetically
tagged pathogens are retained. A syringe pump (d) with a 20 ml syringe withdraws at 10 ml/hr,
pulling fluid through the system. When the sample has finished running, 5 ml of wash buffer is
added to the sample tube in the thermomixer (b) and pulled through the device, washing any
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remaining pathogens into the microdevice and clearing the blood out of the tubing for imaging.
Syringe pump image reprinted from.[I51]
3.2.7 Automated Detection
A biotinylated anti-Candida albicans antibody (Abcam) was labeled with Cy3 streptavidin
(Invitrogen) and diluted to 1/200 in TBS-Tween 20 with 1% bovine serum albumin for staining
of fungi in the device after the washes were complete. Two milliliters of the stain was loaded
into the device and then allowed to incubate for 30 minutes with the pump stopped before the
excess dye was washed out with TBS-Tween 20 and 1% BSA, giving a simple and effective
method to immunofluorescently label pathogens captured in the device.
Working with Abhishek Jain, we placed the device with the magnet on an Axio Observer Z 1
microscope (Zeiss) and employed the lOX objective to photograph the entire capture region of
the device. Metamorphosis image acquisition software controlled the scanning and prepared a
composite of all the acquired images. We then used the MATLAB Image Processing Tool
commands to binarize the image after background removal for automated cell counting.
Sensitivity analysis was done with pathogen numbers in the sample ranging from 0-850 fungi
and compared with manual counting of the same sample.
3.3 Results
3.3.1 Initial Prototypes and Mass Balance Experiment
The initial diagnostic prototype was relatively simple, mainly consisting of channels to
split flow into a central low shear chamber over which the magnets were placed (figure 3.2). The
beads were collected in this low shear chamber from a 10 ml fluid sample. The beads where then
spread along the bottom of the chamber using the magnet and imaged. This system was able to
efficiently concentrate pathogens out of the sample, with less than 2% of the fungi added
escaping into the outlet fluid. But, the detection with this system was very low; detecting less
than 15% of the fungi in the device from saline (figure 3.5 a-b) and less than 3% in bank blood
(figure 3.5 c-d). The primary problem was that the device could not efficiently visualize the
pathogens because they were being buried and obscured by the excess opaque beads required for
timely binding of the rare pathogens. This resulted in low detection rates in both saline and a
blood equivalent (red blood cells at 40% hematocrit) (figure 3.5). I could see the beads forming
a dense pile under the upstream edge of the magnet inside the device that light from the
epifluorescence microscope could not penetrate (figure 3.6). We concluded that to improve
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pathogen detection, the beads and magnetically tagged pathogens needed to be spread thinly
enough so that I could image fluorescent cells through them. This would require us to balance
the magnetic and convective forces on the particles in the microdevice to maximize the bead
spread while still removing all the tagged pathogens.
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Figure 3.5 Results from early device prototypes
(a) Data from initial prototype: This device could capture 98% of the pathogens from the saline
but out only optically detect 13%, leaving 85% of the pathogens captured in the device but
impossible to visualize because they were buried under a dense pile of opaque beads (b)
Detection of C. albicans in saline using early device with WtMBL beads: Despite only being able
to detect a small fraction of the cells, there was a good correlation between total pathogen count
and detected pathogen count, suggesting this could be used for a quantitative readout. (cd)
Detection of C. albicans in Blood Bank blood using early device with WtMBL beads: detection of
fungi in the blood bank blood was even lower, typically only detecting between 2-3% of the
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Figure 3.6 Problem with magnetic beads and optical detection
(a) Stitched Image of bead pileup in channel: In most systems, the beads pile up at the edge of
the magnet, forming the dense pile seen in the channel of one of our early prototypes, burying
most of the captured pathogens and make optical detection difficult. (b) Device cross section
parallel to flow showing bead pile relative to magnet. The preferentially pile under the edge of
the magnet where there is a high magnetic field gradient (c) Device cross section perpendicular
to flow showing pathogens buried in the bead pack. Many are captured but only those near the
surface can be detected with epifluorescence microscopy
3.3.2 Separation Theory
Manipulating magnetic beads in fluid to obtain a desired distribution is a complex
problem with several different factors that must be taken into account, including convection,
fluidic drag, magnetic forces and aggregation behavior. The superparamagnetic beads employed
in our system contain nanometer-sized, single-domain Fe30 4 crystals embedded in a polymer
matrix [142]. These Fe30 4 particles become strongly magnetized in the presence of an applied
magnetic field but no remnant magnetization remains once the field is removed [152].
The magnetic force on magnetic bead (where p is a point-like magnetic dipole) simplifies
down to equation 3.1 where Fm is the magnetic force vector, N is the number of beads attached
and B is the applied magnetic field [152]. In one dimension this relation simplifies down to
equation 3.2 with the force directed parallel to the local magnetic field lines.
Fm = N(p 9 V)B
(3.1)
OB
Fm oc N ax
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(3.2)
As the magnetically tagged pathogen enters and flows along the length of the
microdevice, it comes into close proximity with the external magnet, which induces a magnetic
force in the bead that pulls the tagged pathogen up to the ceiling. The strength of the magnetic
dipole induced in the beads varies with the strength of the magnetic field in a manner which can
be approximated as a hyperbolic tangent [142]. Opposing this motion is the fluidic drag force
(figure 3.7 a). In the microdevice, like other microfluidic systems, viscous forces dominate, so
the Stokes drag equation is a reasonable estimate of the drag force on the particles [133]:
Fd = 6wiirv,
(3.3)
Where Fd is the drag force, rj is the fluid viscosity, r is the particle radius and v, is the
magnetically-induced settling velocity at which the particle is moving toward the ceiling. If we
assume that the channel height is much greater than r and that the magnetic movement of the
dilute beads and pathogens does not affect the bulk fluid flow, we can neglect the shear induced
lift forces on the particle and assume that the forces caused by convection are directed parallel to
the streamlines. This means the settling of the bead in the chamber can be treated as roughly one
dimensional, moving the magnetic particle from the channel up to the ceiling of the chamber.
The horizontal flow towards the outlet sets a time limit on how long this settling has to occur
before the tagged pathogens are carried away from the magnet and the magnetic force drops to
zero (meaning the pathogen was not removed and is lost in the waste fluid). We can equate 3.2
and 3.3 to estimate that vertical separation velocity (vs):
dB
(3.4)
Exactly determining the settling velocity is actually somewhat more complicated, because of the
complexity of the magnetic field, the variation of the magnetic dipole (p.) with the magnetic field
and the tendency of the beads to stochastically start aggregating when they are magnetized, but
the equation above represents the basic behavior.
But getting the magnetically tagged pathogen up to the ceiling of the channel is only part
of the problem, once it's there it must be held in place to control the final spread of the beads and
tagged pathogens for imaging (figure 3.7 b). The main difficulty here is that the magnetic force
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is primarily vertical while the shear induced drag force trying to push the pathogen downstream
is primarily horizontal. The diverging magnetic field lines at the edge of a bar magnet have some
horizontal components, which can help hold the beads in these places. The main problem is that
the majority of magnetic particles are pushed to these points, forming the dense piles that lower
the detection rate of the pathogen.
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Figure 3.7 Forces at work during the separation process
(a) Pulling magnetically tagged pathogen up to the ceiling of the chamber: The magnetic force
pulls the pathogen up towards the ceiling and the permanent magnet as fluid convection pushes
the pathogen parallel to the ceiling. Opposing the magnetic force is the Stokes drag on the
particle. The balance of these two forces results in a settling velocity (vs) towards the ceiling of
the capture chamber. The pathogen must move upward quickly enough to reach the ceiling of the
channel before it swept out of the device by the bulk fluid flow (b) Forces at work on the
chamber ceiling: The primarily vertical magnetic force can do little to oppose the fluidic drag
trying to move the pathogen downstream, either pushing it to a point where there is enough
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horizontal magnetic force (usually at the edge of the magnet, or pushing the tagged pathogen all
the way to the outlet and into the waste. Normalforce not shown. (c) Solution to horizontal drag:
introducing micro features such as wells into the channel ceiling provides a normal force that
can oppose the downstream drag, preventing the beads from being pushed into dense piles at the
magnet edge or lost in the waste. Normalforce not shown.
Micropatterning the channel ceiling with wells provided a simple way to create a
horizontal normal force to oppose the downstream shear (figure 3.7 c). This improved the bead
spread because the tagged pathogens and beads now tended to stay near where they first reached
the ceiling of the channel, but this did little to solve the problem with the magnetic field being
poorly suited for a uniform spread of the magnetic particles.
3.3.3 Altering the Magnetic Field
Based on these empirical and theoretical results, an efficient way of manipulating the tagged
pathogens is by modulating the magnetic field gradient (2- in ID, VB in 3D). I chose to work
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with permanent neodymium magnets rather than electromagnets to avoid problems with
overheating. For a rectangular magnet, the gradient is highest at the edges of the magnet which
causes magnetic beads to preferentially congregate near the edges of the magnet, making
detection of tagged cells difficult. Spreading the beads over a larger area required a more
appropriate distribution of high magnetic field gradient zones. The shape and strength of a field
created by a magnet is dictated by its shape, material and the presence of nearby magnetic
materials (like iron). Altering the shape of the rare earth magnet themselves by CNC machining
was not practical due to their brittleness. Instead, we opted to use a place a ferromagnetic
material in close proximity to the magnet to alter the field (figure 3.8), in much the same way
that a ferromagnetic core is alters the shape of field from an electromagnet [72]. The advantage
of this approach is that ferromagnetic materials are readily machinable, so shaping them is much
simpler. This magnetic flux concentrator can then be placed between the permanent magnet and
microdevice to control VB .
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Figure 3.8 Layout of MFC and microfluidic device
(a) Magnetic flux concentrator made out of permalloy (red), Neodymium Magnet (grey) and
plastic casing (yellow), forming a single, simple to use unit for capturing and displaying
magnetic beads and tagged pathogens (b) Image of beads captured in the system, spread into a
thin layer by the presence of the MFC (c) Cross section of the entire system, showing orientation
of the magnet, MFC and channel relative to each other (not to scale). (d) Top view of the
microfluidic channel layout with close up shot of magnetic beads captured in the microwells
molded into the channel ceiling. The dimensions and spacing of the microwells is indicated on
the diagram.
To determine the optimal shape for this magnetic flux concentrator (MFC), I worked with
Dan Leslie and Karel Domansky to create a finite element model in COMSOL that accounted for
the magnetic saturation of the concentrator material and evaluated a range of geometrical
features machined into the MFC and the magnetic gradient each produced. Tapering the leading
edge of the MFC reduced the number of field lines passing through this area, which had the net
effect of decreasing the gradient spike at the edge of the magnet so that the beads no longer
formed a dense pile in this area. Machining a washboard-like structure into the MFC created
many high gradient zones above the microfluidic channel, which boosted the net field gradient
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along the length of the chamber, making it much more uniform and helping the beads and
pathogens settle more uniformly (figure 3.9 a). In addition, we have also linked the two poles of
the magnet to reduce the forwards projection of the field and decrease possible inference with the
beads before they reached the device. The primary limitation the MFC is that the beneficial
effect of the washboard in the drops off rapidly with distance (having little effect over 700 pm
away from the surface), so we had to bring the magnet as close to the capture channel as possible
(300 pm). Dan and Karel's experimental measurement of the field confirmed that our
simulations were accurate, so I began testing the most promising magnet and MFC combinations
with the microfluidic device.
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Figure 3.9 Characterization of the MFC
(a) Magnetic gradient in the channelfor different magnetic configurations: Purple represents the
magnet alone, showing the large gradient spike that causes the beads to pile up at the upstream
edge of the magnet (dotted red line marks the edges of the magnet). Green line shows the
improved gradient created by the MFC, resulting in much more even distribution of gradient.
The peaks of the sinusoidal pattern correspond to the teeth of washboard in the MFC. Blue
shows the gradient produced by the negative control (magnet positioned above the PDMS but
without MFC). Cartoons under each label show the orientation of the magnet and MFC relative
to the PDMS. (b) Spread of beads produced by the magnet alone, with large number of beads
piling up at the forward edge of the edge regardless of the micropatterned wells (c) Spread of
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beads with the MFC in place, much better distribution, making it possible to directly image
fluorescent cells among the beads
3.3.4 MFC Characterization
Altering the magnetic field with the MFC allowed me to spread the beads in the channel
much more effectively than was possible with the magnet and channel dimensions alone. I
experimented with different channel dimensions to optimize spreading the 1 pm magnetic beads
into a thin layer so that I could image the fluorescently labeled pathogens among them while still
ensuring removal of more than 99% of the magnetic particles from the flow (figure 3.9 b-c).
Overall I found that a 280 pm high by 3 mm wide channel gave the best results, which gave a
wide enough cross section to operate at 10 ml/hr while minimizing bead capture variation across
the width of the channel, which was a problem with taller channels. With these dimensions, I
could pull reliably pull the magnetic beads up to the ceiling of the channel and had tuned the
magnetic and drag forces so that the beads only stopped moving if they settled into one of the
microwells, producing a much more uniform, planar pathogen distribution that could be easily
scanned over with a microscope.
The bead spread was best with the MFC in place, although the spread was also acceptable
if the MFC was removed from the plastic holder (preserving the spacing of the magnet above the
device), but the strength of the magnetic gradient in the channel was much weaker with this
configuration. These initial experiments were conducted with 1 pm beads only, so I suspected
that that without the MFC to focus the field, the magnet in the plastic holder would not exert
enough force on the beads to capture the larger magnetically tagged pathogens. The magnetically
tagged pathogens would experience a similar amount of magnetic force to the beads but a higher
Stokes drag due to their larger size and would therefore need either a stronger magnetic field
gradient or a longer channel for effective capture [133]. To see if this was the case, I began
testing the system with both beads and pathogens.
3.3.5 Detection of Pathogens
In the microdevice, there is a trade off between ensuring complete binding of the pathogens
and optical detection. With too many FcMBL beads in the sample, the captured pathogens are
much more likely to be buried. With too few beads added to the sample, pathogen capture is
incomplete, so there are unbound pathogens that are not retained in the device. In saline I found
the best balance between these two opposing factors as 2 ptg 1pm beads/ml (figure 3.10), using
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more or less beads caused the detection rate to decrease. However, I had to increase the bead
concentration up to 10 pg 1p [m beads/ml for adequate capture in the blood.
Binding and detection of fungi directly in blood proved variable because we were still
optimizing pathogen capture. With the MFC, I could detect up to 34% ± 8% fungi spiked into the
blood. Using the magnet alone, I detected 25% ± 8% of the pathogens in blood, but could not
show a significant difference between the two due to the variability of pathogen binding in
blood, leading to large error bars for both configurations (figure 3.11 a).
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Figure 3.10 Detection of C. albicans in microdevice vs. bead concentration
Because the opaque microbeads can obscure the pathogens in the sample, I tried to minimize the
amount of beads used. At too high of a bead concentration, the excess beads tend to bury more of
the pathogens, but if the bead concentration in the sample is too low, not all of the pathogens
were be bound, resulting in lower capture and detection.
To get a better look at pathogen detection with the device, I removed the initial binding as a
factor in the system by attaching magnetic beads to the pathogens before they were spiked into
donor blood. I found that I could detect significantly more fungi in saline with the MFC (0[=0.05)
compared to the magnet only or the magnet in the plastic MFC holder. With the magnet directly
on the PDMS, the beads still formed a pile under the upstream edge that buried a large fraction
of the fungi so that I could only detect 47% ± 1% of the C. albicans seeded into a 10 ml saline
volume (figure 3.11 b). With the magnet in the MFC plastic holder (negative control), detection
was slightly better at 52% 4% of the fungi. With this configuration, tagged fungi were captured
right up to the downstream edge of the magnet, consistent with my hypothesis that the weaker
magnetic field gradient produced by this configuration was insufficient to capture all the tagged
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fungi from the flowing sample. Adding the magnetic flux concentrator boosted the detection up
to 68% L 4% of the 850 fungi added to a 10 ml volume of saline, significantly better than the
magnet only configuration.
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Figure 3.11 Detection of C. albicans in Saline and Blood
(a) Binding and Detection of C. albicans in Saline and Blood in simulated septic sample. Magnet
with MFC performs significantly better (a=0.05) than either magnet only configuration,
detecting 68% of the fungi added to a 10 ml saline sample. The system can detect up to 34% of
the fungi in blood. Large error bars in blood result from binding variability in blood from
different donors. (b) Comparison of detection with and without MFC in both saline and blood.
Significantly better detection of pathogens in both saline and blood with MFC when the initial
binding is ignored (a=0.05, error bars exp. Error). Detection levels in blood and saline are
almost equivalent with pre-bound pathogens, showing that this system can significantly boost
optical detection of magnetically tagged pathogens. (c) Image of immunofluorescent stained C.
albicans assembled from automated scan of microdevice: In the enlarged pictures, individual
pathogens in the microwells can be seen.
In the blood (diluted 1:1 with saline) with pre-bound fungi, I confirmed that combining the
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magnet with and MFC significantly improved detection of captured fungi in the device (c=0.05).
I could detect up to 67% E 7% of the pathogens added to the sample, nearly equivalent to the
detection rate in saline. Using the magnet alone to pull out tagged fungi, I could only detect 43%
± 4% of the pathogens added to the sample. The spread of the beads in blood was similar to that
seen in saline, with the magnet only causing a pile of beads at the leading edge of the magnet
which could have definitely buried some of the tagged fungi while the spread with the MFC was
much more even, with beads and cells captured almost exclusively in the micropatterned wells.
The high detection rate in blood means that the system could pick up fungal concentrations down
to 1 cfu/ml, which would translate to visualizing 3 out of the 5 total pathogens in the 5 ml blood
sample (10 ml after dilution).
3.3.6 Automated Counting
By using the MFC to spread the beads out more evenly in the channel, I was able to place
all the pathogens in a single focal plane, greatly facilitating automated scanning of the captured
pathogens. These fluorescent images obtained from this scanning were stitched back together
and fed into an automated counting program that Abhishek Jain designed (figure 3.11 c). By
manually and automatically counting the same microdevice, we found that once the thresholding
values on the program had been set correctly, the automatic program was able to correctly
quantify the pathogens within ± 10% of the manual count and correctly detect when no fungi
were present in the device. The only downside to using an fluorescent detection method was
getting a specific stain bright enough for detection, given our current image processing program.
Calcofluor worked well in both blood and saline, but the immunofluorescent staining had a much
weaker signal intensity in blood. More advanced image processing techniques would increase the
flexibility of automated counting system by analyzing the pathogen shape and size as well.
3.4 Discussion
I have developed a simple microfluidic system using the general magnetic opsonins and
shown that it can magnetically opsonize and visualize up to 67% of the fungi from blood in less
than three hours, more than 20 times better than my initial prototype. This system can detect
down to 1 fungus/ml in human blood, making it potentially useful as a rapid sepsis diagnostic for
fungemia. The tagged pathogens can then be concentrated in a microdevice, increasing the
pathogen density to the point where they can be directly detected.
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Fabrication of the device proved difficult because I was trying to combine millimeter
scale channels with micropatterned features on the ceiling of the channel. The SU-8 photoresist
used to create most soft lithography molds can usually only create tall 100 pm features while the
channel employed in my device was 280 pm tall. Deep reactive ion etching (DRIE) could be
used to create such a mold, but it is a expensive process, requiring special photolithography
masks and fabrication equipment, making it unsuitable for rapid device prototyping [153].
Instead I used Mylar channels (created with the plotter cutter) and then combined these with
micropatterned PDMS (made with traditional soft lithography methods) to produce a hybrid
device that I cast in epoxy to make the actual device mold [154]. This gave me a rapid,
inexpensive way to produce the devices with the proper combination of dimensions that the
system required.
The typical magnetic field created by a block magnet has a strong gradient spike near its
edges, which caused the excess magnetic beads in the channel to form a dense pile that obscured
the captured fungi. Introducing a MFC made of a ferromagnetic material allowed us to redirect
the magnetic field lines and alter the gradient creating the magnetic force on the FcMBL beads.
Various other groups have employed electromagnets with custom pole pieces or microfabricated
electromagnets inside of the device to achieve a similar purpose [72, 155]. These approaches
work well, but I calculated the power draw required for an electromagnet to maintain a field
comparable to the permanent magnets I was employing would rapidly overheat, so we opted for
a simpler, more reusable approach. Simulations of different MFC shapes allowed us to find a
suitable design and experimental measurements confirmed that the simulations matched well
with reality. I found that the MFC did greatly improve the spread of the magnetic beads in the
microdevice, although the fluid convection in the channel needed to be optimized as well to
correctly balance the drag and magnetic pull on the particles.
I employed the conditions I had previously found to give good pathogen binding in
blood, although there was a tradeoff between pathogen detection and higher beads
concentrations, so I compromised and used 5 pg of 1 pm FcMBL/ml sample. Despite this, the
variability of pathogen binding in blood was still making it difficult to confirm what effect the
MFC was having on pathogen detection, so I switched to attaching the beads to fungi before they
were added to the blood to focus only on the detection. This allowed me to confirm that adding
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the MFC into the system significantly improved detection over a device without a MFC to
modulate the magnetic field gradient created by the block magnet.
There are several methods for continuous size based separation of particles in
microfluidic devices, potentially letting us use a larger bead concentration for binding and then
remove the majority of excess beads before they enter the detection device. However, very few
of these separation methods are capable of operating at flow rates of 10 ml/hr and their use is
complicated by the non-Newtonian characteristics of blood, which makes the precise fluid
behavior difficult to predict accurately enough for the separation to work [156]. Mach et al had
to dilute blood to 1/10x before they could use inertial focusing for sized based separation in
blood, which would increase our sample volume from 10 ml up to 50ml, greatly increasing the
time required for detection [157]. Immunofluorescent staining of pathogens after they had come
in contact with blood also proved difficult although it worked well in saline. Our belief is that the
endogenous antibodies in the blood were blocking all the antigens on the pathogens before our
staining process occurred. In future versions, we would most likely switch to using Fluorescent
In Situ Hybridization (FISH) to fluorescently label the pathogens in addition to the calcofluor
dye, which would not suffer from this surface blocking problem and can be used for general or
species-specific identification of the pathogens [28].
The microdevice system works well for concentrating and detecting fungi bound with 1
ptm beads. But, I found it was poorly suited for the optical detection of bacteria, due to the fact
the binding of 1 pim beads to bacteria is low and the system is not optimized for capturing the
smaller 128 nm beads out a flowing sample, although it should be possible to redesign the device
to work with these beads. Joo Kang at the Wyss Institute has designed a system that can
continuously separate bacteria tagged with the 128 nm FcMBL beads out of blood which could
be adapted for optically detecting bacteria [143]. The smaller bacteria are also much harder to
visualize than the fungi. For these reason, I focused on using the FcMBL beads for PCR
identification of bacteria out of blood in the next chapter instead of adapting this optical
detection system.
Combining the MFC with the device I developed allowed us to create a system that could
detect up to 67% of the magnetically tagged fungi in either a 10 ml saline or 5 ml blood sample
in less than three hours. Even when I did not prebind the fungi with beads, I was still able to
detect 34% of the pathogens out of blood. This proves that the FcMBL beads can be used to pick
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out fewer than 850 fungi among more than five billion humans cells and, with the proper fluid
and magnetic manipulation, display them for detection. The system itself is simple to run and
operate, with the most expensive part being the fluorescent microscope for detection, although
Daniel Levner at the Wyss has produced a comparable microscope that can be assembled for less
than $5,000, putting the price of this diagnostic system well within the range of small clinics, not
just large hospitals. A simple, rapid method for detecting fungal sepsis could greatly reduce the
mortality rate for this type of infection. Currently, detecting fungi in the blood stream takes 3-7
days because the organisms grow much more slowly than bacteria [158]. The antifungal
medications required to treat the infection are much more toxic than antibiotics, so many
clinicians prefer to have a definitive diagnosis before administering them [10, 159]. These two
factors mean that patients with fungal sepsis can go for days without effective treatment, so they
can progress into the late stages of sepsis, resulting in a 60% mortality rate even with the state of
the art medical care [19]. The FcMBL beads combined with this detection system could offer
clinicians a way to confirm or deny the presence of fungi in the blood in a matter of hours and
start antifungal treatment right way, greatly increasing the patient's chances of successful
treatment and a full recovery.
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Chapter 4 PCR Detection of Bacteria
4.1 Introduction
PCR has sufficient sensitivity to detect pathogens in septic blood directly and various
groups have explored using PCR, nested PCR, qPCR and multiplex PCR in both conventional
benchtop and microfluidic systems to rapidly detect the presence of pathogens in blood [61].
However, these groups have encountered difficulty in realizing the full potential of this
amplification method because blood contains a large amount of PCR inhibitors that interfere
with the reaction and greatly reduces the sensitivity of the assay [69]. Substances such as
hemoglobin, leukocyte DNA, calcium, and most anticoagulants (including EDTA and heparin)
abound in blood and can completely inhibit PCR amplification, which is the main reason why no
PCR sepsis diagnostic is currently approved be the FDA for clinical use [69]. A few commercial
kits are available for isolating bacterial DNA out of blood, but even the best of these has a
maximum sensitivity of 50 cfu/ml [29, 160]. Meanwhile, the pathogen load in septic blood may
be 1 cfu/ml or fewer [16]. In this chapter, I discuss using the FcMBL beads to isolate bacteria
from blood in order to boost the reliability of PCR detection in blood. I previously found in
chapter 2 that commercial magnetic systems (such as the DynaMag 2 rack) could not reliably
separate bacteria tagged with 128 nm FcMBL beads out of blood (which is the bead size best for
binding bacteria). To overcome these limitations, I designed a more effective magnetic
separation system which significantly improved recovery of tagged bacteria out of blood and
used this new system to create a simple method to separate and concentrate bacteria tagged with
FcMBL magnetic beads out of blood while removing the vast majority of PCR inhibitors at that
same time. I have shown that this method can separate bound bacteria from blood and purify
them for PCR or qPCR identification. However, the FcMBL beads pull out enough white blood
cells (containing human DNA) during the magnetic separation to partially inhibit the PCR
reaction and reduce its sensitivity. After this contaminating DNA is enzymatically degraded (the
Hybrid sample prep method), the FcMBL beads show comparable sensitivity to existing
commercial methods. This FcMBL bead sample preparation method can also be easily adapted to
detect bacterial contamination in other complex samples such as food, demonstrating the
versatility of this technology as the basis for rapid pathogen detection systems.
4.2 Materials and Methods
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4.2.1 Making a better magnetic rack
Several different magnet shapes and arrangements were modeled with finite element
software in COMSOL to develop a better magnetic separation rack. The magnitude of the
magnetic gradient at the inner wall of the sample tube and near its center were calculated and
used to compare the different configurations. Several different permutations of rectangular and
ring magnets, with different numbers, sizes and orientations, were investigated, looking for one
that gave both a high maximum magnetic gradient and a high average gradient strength in the
sample volume.
The Hex Rack was found to be the best of the configurations tested. It consisted of six
magnets arranged in a hexagonal pattern around a BD FACS 12x75-mm tube (5 ml volume)
(figure 4.1 a-c). Instead of positioning one magnet on one side of the tube (as is done in the
DynaMag 2 rack), the Hex Rack was designed to completely surround a FACS tube (5 ml
volume), minimizing the distance between the sample fluid and the magnets (which contact the
outside of the tube directly). The 12x75 mm tubes fit well with the available 2 inch (50.8 mm)
long magnets (neodymium N42 magnets, K & J magnetic, 2"x0.25"x0.25") and have the thinnest
wall of a conventional test tube, making them well suited to this application. Through previous
experimentation (chapter 3), I found that the gradient for a rectangular magnet is strongest at the
corners where the field lines diverge outwards, so this rack places the edges of the six magnets
directly against the tube surface to exploit this phenomena. Alternating the direction of the
magnetic poles helps to create interlacing field lines through the entire volume of the tube
(figure 4.1 c) rather than circling the rim (which is the case if they all had pointed the same
direction), again boosting the magnetic gradient. The bottom of the magnets end 5 mm from the
bottom of the tube, so any magnetic beads near the bottom are drawn to the particularly strong
field at the bottom corner of the magnets, lowering the likelihood that they will be lost when
fluid is aspirated out of the bottom of the tube. The 5 ml volume of the tubes also makes it
possible to handle a much larger sample volume than was previously possible (DynaMag 2 has a
maximum volume of 2 ml), increasing the sensitivity our assay. This technology can scale up for
larger tube sizes as well.
Once the geometry had been optimized, an acrylic rack to hold the magnets and sample
tube in the correct orientation relative to each other was designed in AutoCAD. The patterns
were cut out of 1/4" and 1/8" acrylic sheets (McMaster) using an Epilog Legend 36EXT laser
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cutter. The plastic holders were assembled, glued together with acrylic cement and then the
magnets were inserted, at which point they were ready for use.
To estimate the gradient strength of the DynaMag 2 rack (Invitrogen), one of the racks
was disassembled and calipers used to determine the dimensions of its magnets and their
orientation relative to the sample tube in the device. These dimensions were used to create a 2D
cross-sectional model of the rack in COMSOL. The magnets were assumed to be made of grade
N42 neodymium (one the most powerful magnetic materials available). The finite element model
was used to calculate the strength of the magnetic gradient in the commercial rack.
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Figure 4.1 The Hex Rack
(a) The Hex Rack, constructed from six permanent magnets held together with a clear acrylic
holder (b) Hex Rack with the 12x75 mm FACS tube it was designed to hold (c) Heat map of
magnetic field in the cross section of the Hex Rack generated with finite element modeling in
COMSOL. The black lines indicate the direction of the magnetic field lines and the white arrows
indicate the direction of the pole in each magnet, showing the alternating pattern (d) Magnetic
gradient strength in the Hex Rack and DynaMag 2 rack. Finite element modeling was used to
predict the magnetic field gradient in each rack. The Hex rack has a higher average and
maximum magnetic field gradient. DynaMag 2 image reprinted from [161]
4.2.2 Magnetic Enhancement Beads (MEB)
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Magnetic enhancement beads (MEB) were used as a second strategy to boost the
separation and retention of 128 nm FcMBL bead tagged bacteria from of blood. To evaluate
how much the MEB concept helped with magnetic separation, testing was conducted using the
Kingfisher Flex Magnetic Particle Processor equipped with a 96 deep well magnetic head
(Thermo Scientific). This machine is able to automatically perform magnetic separations in a
very reproducible manner by inserting a magnetic head, sheathed in removable plastic, into
either 24 or 96 well plates and has been used at the Wyss Institute for high throughput magnetic
testing with 1 pm FcMBL beads [124]. This machine has not been able to reliably remove 128
nm beads from diluted blood because the magnetic gradient it generates is not strong enough.
The binding and separation of E. coli out of diluted blood was evaluated in this system using 128
FcMBL beads for binding and different concentrations of MEB to boost separation efficiency. A
modified version of the depletion assay with 1 ml samples in a 96 well deep well plate was run.
F. coli at 4,400 cfu/ml were added in triplicate to EDTA blood diluted 1:4 with TBS-Tween 20
with 5 mM calcium. Ten mM of glucose and 0.8 mg heparin per ml (JT Backer Inc.) were added
(conditions which Nazita Gamini and Martin Rottman had determined gave optimal binding with
this system [124]). Fifty micrograms of 128 nm FcMBL beads per milliliter sample were then
added and the plate was placed in a thermomixer running at 950 rpm for 20 minutes for binding.
After the binding was complete, 0, 5, 12.5 or 25 pg of 1 or 2.7 pm biotin and BSA blocked
beads/ml were added to the 128 nm bead samples to act as aggregation aids. The plate was
transferred onto the KingFisher and the magnetic head and protective plastic comb were lowered
into the wells for a 7.5 minute magnetic separation. After the separation was complete, the beads
and bound pathogens were withdrawn from the deep well plate along with magnetic comb when
it was raised and moved to a new plate. Then the depleted sample was plated out using an Eddy
Jet Spiral Plater. The colonies were counted the next day and the each of the samples was
compared to a positive control to determine the amount of F. coli bound at each MEB
concentration.
4.2.3 FcMBL Sample Preparation Procedure
The utility of the FcMBL beads and new separation systems for concentrating and
purifying bacteria for PCR were tested in a range of fluids (donor blood diluted 1:1 with saline,
20% hematocrit red blood cells in saline from the blood bank or saline). A frozen F. coli aliquot
was reconstituted in TBS-Tween 20 buffer with 5 mM calcium and serially diluted to create a
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range of pathogen concentrations. For experiments using pre-bound bacteria (removing binding
as an experimental factor), one hundred microliters of these concentrates were added into
different 5 ml FACS tubes. Fifty gg of 128 nm FcMBL beads were added and given 10 minutes
to bind to the concentrated E. coli before 2 ml of sample fluid (donor blood diluted 1:1 with
saline, 20% hematocrit red blood cells in saline from the blood bank or saline) was added to the
tube along with 25 pg of blocked 1 pm beads to act as MEB (section 4.2.2) and mixed by
inversion. For direct binding in the sample, the E. coli were spiked into 2 ml of sample fluid and
then the 128 nm FcMBL beads added. These were placed in an inverting mixer (Hula Shaker,
Invitrogen) for 20 minutes, after which time the MEB were added and mixed briefly by inversion
(figure 4.2 a-b).
At this point, the samples were placed in the Hex Rack for a 20 minute magnetic
separation (figure 4.2 c). After the separation was complete, the blood was slowly aspirated from
the tube using a 5 ml pipette and 3 ml of TBS-Tween 20 with 5 mM calcium buffer was added to
wash the tubes (while they were still in place on the rack) (figure 4.2 d). After five minutes, the
3 ml wash buffer was aspirated out and replaced with 1 ml of fresh calcium buffer. Then, the
tubes were capped and removed from the racks and gently agitated to resuspend the beads and
tagged pathogens (figure 4.2 e). Then they were replaced in the rack and given 10 minutes to
magnetically separate again (figure 4.2 f). This moved the beads and bacteria down the tube
walls so that they were all resuspended in the 1 ml wash buffer. After the separation was
complete, one more 1 ml wash was added and given five minutes to incubate before the final
wash was aspirated (figure 4.2 g) and 50 pl of distilled water was added. At this point, the tubes
were removed from the rack and vortexed at maximum speed for 10 seconds to resuspend all the
beads and tagged pathogens, which were then transferred to a DNA extraction tube (figure 4.2
h). The vortexing procedure was repeated with a second water wash (30 pl for PrepGEM DNA
extraction or 50 pl for DNeasy kit) to collect any remaining pathogens from the FACS tube. At
this point, the samples were ready for DNA extraction using either the PrepGEM or DNeasy
extraction kits (see section 4.2.6).
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Figure 4.2 FcMBL sample preparation method
4.2.4 MolYsis Sample Preparation Procedure
Preparation of E. coli spiked samples was the same as for the FcMBL method (section
4.2.3). These samples were in 2 ml microcentrifuge tubes instead of 5 ml FACS tubes without
any FcMBL or MEB beads added. Pathogen recovery from the undiluted blood or saline samples
was carried out with a MolYsis Basic 5 kit (Molzym) according to the manufacturer's
instructions. Briefly, CM buffer (250 pl for 1 ml samples or 2 ml for 5 ml samples) was added to
the samples (figure 4.3 a-b), vortexed and incubated at room temperature for 5 minutes to
selectively lyse all the human cells in the sample. Then DB 1 buffer (250 gl for 1 ml samples or 2
ml for 5 ml samples) and 10 gl of MolDNase B was added and incubated in the sample for 15
minutes, breaking down all of the human DNA in the sample (figure 4.3 c). Then the samples
were centrifuged at maximum speed for 15 minutes. The pellet was resuspended in 1 ml of RS
buffer and then centrifuged again at maximum speed for five minutes (figure 4.3 d). The pellet
was then suspended in 80 pl of PL buffer with 20 g1 of BugLysis solution (figure 4.3 e) and
incubated in a thermomixer (Eppendorf) at 37*C, 1000 rpm for 30 minutes, after which the DNA
was extracted from the sample using a DNeasy solid phase extraction kit for blood and tissue
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(Qiagen) (figure 4.3 f). The MolYsis kit required proteinase K digestion, so the PrepGEM DNA
extraction method did not work (see section 4.2.6).
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Figure 4.3MolYsis sample preparation method
Image adapted from [162]
4.2.5 Hybrid Sample Preparation Procedure
In order to see if pre-concentration with MBL beads could make the MolYsis kit more
effective, samples were run using the FcMBL procedure (section 4.2.3) until the beads and
captured pathogens had been resuspended in the 1 ml of buffer (figure 4.4 a-e). At this point the
samples were processed with the MolYsis kit (section 4.2.4) using the procedure recommended
for 1 ml samples according to the manufacturer's instructions (e.g. 250 sl of CM and DB 1 buffer
were used, everything else stayed the same) (figure 4.4 f-h). DNA was then extracted from the
concentrated bacteria using a DNeasy kit (Qiagen) (figure 4.4 i).
Add MEB
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Figure 4.4Hybrid sample preparation method
Image adaptedfrom [162]
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4.2.6 DNA Extraction
DNA for PCR was extracted from the recovered beads and pathogens using either the
DNeasy Blood or Tissue Solid Phase Extraction (SPE) kit (Qiagen) or the PrepGEM Bacteria
enzymatic kit (Zygem) according to the manufacturer's directions.
For the DNeasy kit, the samples were incubated with ATL buffer and proteinase K for 15
minutes at 56*C in the thermomixer (Eppendorf) at 1000 rpm to digest the cell walls of the
bacteria and release their DNA. The digested bacteria were then diluted with equal parts AL
buffer and pure ethanol before being added to the solid phase extraction spin column. The
columns were spun at 8,000 rpm for 1 minute, with the DNA released from the bacteria being
retained in the column matrix and the rest of the proteins and liquid passing through into the
waste. The columns were washed twice more with the supplied buffers and then 100 p1 of AE
elution buffer was added to the column and allowed to incubate at room temperature for one
minute to resolubilize the DNA in the column matrix. The eluted DNA was then collected in a
fresh 1.5 ml microcentrifuge tube in a final centrifugation step.
The PrepGEM Bacteria kit took a similar amount of time to run as the DNeasy kit,
however it had much less hands on time because it was a closed tube procedure that did not
require centrifugation. This method used lysozyme enzymatic digestion to break down the cell
walls. It also contained the PrepGEM enzyme, which is responsible for digesting intracellular
proteins, particularly DNases that might break down the sample. Twenty microliters of buffer
containing these enzymes were added to the 80 pl of purified beads and bacteria, then sealed into
a PCR tube strip and placed in a Tetrad 2 Peltier Thermal Cycler (BioRad) for the temperature-
dependent extraction. The samples were heated to 37*C for 15 minutes (giving the lysozyme
maximal activity), then held at 75 0C for 15 minutes (giving the PrepGEM enzyme maximal
activity) and finally incubated at 95*C for 15 minutes (degrading both extraction enzymes so that
they did not interfere with subsequent PCR reactions). This method had much less hands on time
than the solid phase extraction method. This meant it had less potential for contamination or
human error and was easier to automate, making it more favorable from a procedural
prospective. Extracted DNA was either analyzed immediately or stored at -80*C for later
analysis. Each PCR assay took less than 10 pl of the extracted DNA so many different tests were
possible on a single sample. Concentration and purity of the extracted DNA was assayed using a
Nanodrop 2000 Spectrophotometer (Thermo Scientific). The absorbance spectra of a sample
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were measured using 2 pl of liquid. The machine was calibrated using distilled water before each
batch of samples. Concentration of double stranded DNA was calculated from the absorption of
sample in the 260 nm wavelength and an estimate of the protein contamination determined from
the absorption ratio at 260 nm and 280 nm.
4.2.7 Bead interference with DNA extraction
To determine if the FcMBL and aggregation aid beads interfered with DNA extraction,
different concentrations of the beads (0, 10, 20, 30 jig 128 nm FcMBL beads with half that mass
of MEB) were added to 8,000 E. coli in 80 pl TBS with Tween 20. DNA extraction with the
PrepGEM kit (section 4.2.6) was then carried out and qPCR (section 4.2.9) was used to
determine the relation between Cq and bead concentration.
To check for pathogen losses during the binding and washing process, a similar
experiment was carried out in a larger fluid volume. The same amount of bacteria and range of
128 nm FcMBL beads were added to 1 ml of TBS-Tween 20 with 5 mM calcium and given 20
minutes in the inverting mixer to bind. Then the MEB were added (one half the mass of the 128
nm FcMBL beads added) and the samples were placed in the magnetic rack and given 20
minutes to separate. The saline was then aspirated our and replaced twice before the beads and
captured pathogens were resuspended in 80 pl of water for PrepGEM DNA extraction and
subsequent qPCR analysis (see section 4.2.10). The Cq (threshold cycle) results from these
bound and washed samples were compared to the first set of samples to determine if any E. coli
were lost during the binding and washing procedure.
4.2.8 PCR and qualitative analysis
The initial phases of testing were carried out using normal PCR and known
concentrations of bacteria to evaluate the approximate efficiency and sensitivity of the FcMBL
preparation method and the behavior of the various primer sets selected. Four highly specific
primers for E. coli, dubbed EcA, EcB, EcC and EcD were selected from a paper by Maheux et al.
for testing [163] (table 4.1). These primers showed the best selectivity of the nine evaluated in
that paper and had product lengths compatible with qPCR.
PCR was carried out using 8 pl of the extracted DNA sample, 500 nM of the forward and
reverse primers and Phusion High-Fidelity PCR Master Mix with HF buffer (New England
Biolabs) in a 20 pl volume. The samples were maintained at 4*C using a cold block inside of an
Air Clean 600 PCR Workstation (USA Scientific) during preparation (in a separate location from
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the sample preparation and DNA analysis areas to minimize the chances of cross contamination).
The samples were placed in PCR tube strips and heated in a Tetrad 2 Peltier Thermal Cycler
(BioRad), preheated to 98'C. The samples were treated at 98"C for thirty seconds to initially
denature the double stranded DNA, then cycled through 98*C for 10 seconds, annealing for 30
seconds (temperature dependent on primer set, see table 4.1), and elongation for 40 seconds for a
total of 35 cycles. After the cycles were complete, the samples were held at 72*C for 10 minutes
to finalize any last elongations and then held at 4*C until ready for gel electrophoresis.
The results of the PCR were analyzed using gel electrophoresis. Ten microliters of each
sample and 5 pd of water were added into each well of 1% agarose E-Gel (Invitrogen), with 56
ng of 100 BP ladder (Invitrogen Ca# 15628-050) for comparison. The gels were run for 9
minutes on an E-Gel Ibase (Invitrogen), 1-2% agarose setting, and then imaged using the SYBR-
Green Safe setting on a FluorChem M Imager (Protein Simple). The band intensity was analyzed
using ImageJ software and normalized relative to the band intensity of the DNA ladder (which
was the same for all the gels). The PCR amplification was deemed positive if the resulting
product band intensity was above the nonspecific background in the 0 cfu/ml sample (run in each
experiment). In addition to this negative control, the fidelity of the DNA extraction and PCR was
checked using a sample containing 48,000 E. coli in saline and no E. coli in saline (positive and
negative controls).
4.2.9 Primer Evaluations
The four E. coli primers (table 4.1) were characterized using DNA extracted from a
range of E. coli or K. pneumoniae concentrations (in triplicate) in saline to check for bacterial
specificity. PCR and band analysis was conducted using the procedure outlined in section 4.2.8.
The usefulness of each primer set was evaluated by checking for the formation of the intended
product and presence of any non-specific amplification products in the E. coli samples of any
amplification at all in the K. pneumoniae samples.
The specificity of the two best primer sets (EcA and EcD) was assayed in the presence of
human DNA by amplifying DNA from E. coli purified from fresh human blood of ten different
donors using FcMBL beads (see section 4.2.3). Each primer was then used to amplify E. coli
extracted from donor blood and evaluated to see if there was non-specific amplification of
human DNA, particularly in the 0 cfu/ml samples.
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TEcol754 5'- CAGTACAGGTAGACTTCTG -3'
UAR900 5'- ACGCGTGGTTACAGTCTTGCG -3'
EcC uidA 61 166 UAL1939b 57 ATGAATTTGCCATTTTG -3'
UAL2105b 5'- ATTGTTTGCCTCCCTGCTGC -3'
ECD uidA 62 147 UAL 5 -TbGTAA T TACCGACGAAAACCGC-.3
UAR 5'- ACGCGTGGTTACAGTCTTGCG -3'
Table 4.1 E. coli specific primers tested for amplifying bacteria extracted using FcMBL Sample
Prep
Table adapted from [163]
4.2.10 qPCR analysis
From the primer characterizations, the EcD set was found to be the most reliable, forming
a specific product with minimal non-specific amplification of human DNA, making it the most
suitable for qPCR testing. SYBR@ Green PCR Master Mix (Applied Biosystems) was used for
the assay.
A genomic standard was chosen the for qPCR quantification since the uidA gene (target
of the EcD primers) has only one copy per bacteria [164] and size of the genome for the E. coli
strain employed in the experiments (ATCC 8739) was known [165]. From this I calculated that
52.9 ng of extracted DNA should contain 107 copies of the target gene. To obtain purified DNA
to make standard aliquots, E. coli were grown in LB broth at 37*C overnight. The bacteria were
checked under the microscope for any signs of contamination and then DNA was extracted from
600 pl of the culture medium using the DNeasy extraction kit. The purity and concentration of
the extracted DNA was determined using the Nanodrop spectrophotometer and then the purified
DNA was diluted to 10.6 ng/pl (so that 5 pl would contain 107 gene copies) and 20 pl of this
standard was aliquoted into individual PCR tubes and stored at -80*C until needed. A standard
curve was created by making seven ten-fold serial dilutions of the standard. Five pl of each
dilution, along with a no template control was run in duplicate for each qPCR run, giving
concentrations ranging from 107 to 100 gene copies in water that could be used to confirm the
qPCR was working and give a comparison for samples purified from blood.
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Primer concentration optimization was performed according the procedure in the SYBR
green user guide with the standard DNA using a 50 pl sample volume. Fifty nanomolar of the
forward and reverse EcD primer set was found to be the most effective, showing only a single
product with a size of approximately 150 BP and no amplification in the no-template wells.
qPCR analysis of the samples was conducted using 45 ptL of SYBR green mastermix,
containing 50 nM of the EcD primer set and 5 pI of sample. Amplification and fluorescent
analysis was performed in a Cl000 Thermocycler equipped with a CFX96 Real-Time System
(BioRad) using the two step amplification recommended for the kit (10 minutes at 950C to
activate the hot start DNA polymerase, then 45 cycles with 15 seconds at 950C to denature the
double stranded DNA and 60 seconds at 60'C (for annealing and elongation). The intensity of
the SYBR and FAM fluorescence was read after each cycle and a melt curve analysis was
conducted after the final amplification step to check for non-specific amplification. The CFX
manager 3.0 software calculated the threshold cycle (Cq) from the measured fluorescence
readings using the default settings. Gel electrophoresis (section 4.2.7) was conducted on
individual samples to confirm the results of the melt curve analysis were accurate, particularly if
any non-specific amplification was suspected.
4.2.11 PCR detection of bacteria from food
To show that the FcMBL beads could be used for a wide range of sample types, the
FcMBL sample preparation procedure was adapted to work with homogenized food samples,
including yogurt and oat cereal. For binding and detection of E. coli detection in yogurt, tests
were conducted in plain nonfat yogurt (Dannon), Greek-style nonfat yogurt (Chobani) and
Greek-style nonfat strawberry yogurt (Chobani). PCR with EcD primers was performed to make
sure that the amplification was not inhibited by trace amounts of yogurt. Plain, nonfat yogurt was
added into TBS-Tween 20 buffer with 5 mM calcium at 1 gm yogurt to 100 or 1000 ml buffer
and added a range of E. coli concentrations (between 0 to 5000 cfu/ml). Then the DNA was
extracted using the PrepGEM kit and PCR was performed on the samples (using the procedure
laid out in section 4.2.7.
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Figure 4.5 Modified FcMBL sample preparation method for isolating bacteria from food
samples
Different dilutions of yogurt were tested to see how much the yogurt needed to the
diluted with calcium buffer for binding of E. coli to be reliable. Dilutions of yogurt to buffer
ranged from 1 gram: 1 ml to 1 gm: 9 ml with either 100 or 0 E. coli per ml (figure 4.5 a). The
yogurt was mixed into the buffer by pipetting and then vortexing at full speed for 30 seconds
(figure 4.5 b). Twenty five micrograms of 128 nm FcMBL beads/ml sample were added and the
samples were placed in an inverting Hula Mixer (Invitrogen) for 20 minutes for binding (figure
4.5 c). The MEB were then added (12.5 pg 1 tm blocked beads/ ml) and the samples were
placed in the Hex Rack for 20 minutes (figure 4.5 d). The yogurt solution was then aspirated and
replaced with 3 ml of calcium buffer (figure 4.5 e). After five minutes, the first wash was
removed and the sample resuspended in 1 ml of calcium buffer (figure 4.5 f) before being
replaced in the rack (figure 4.5 g). The beads were given ten minutes to separate again and then
the final wash was aspirated (figure 4.5 h). Then the tube was removed from the magnetic rack
and the beads resuspended in 80 pl of water and submitted to the PrepGEM DNA extraction kit
(figure 4.5 i) (section 4.2.6). Qualitative PCR analysis was then performed on all the different
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samples, and only the highest dilution, I gram yogurt to 9 ml of TBS-Tween 20 buffer, showed a
reliable PCR signal. This dilution factor was used for future experiments.
The approximate sensitivity of the assay was then determined using this dilution of
yogurt (Plain nonfat from Dannon, Chobani 0% fat Greek-Style, Chobani 0% fat strawberry) by
adding a range of E. coli to the 4.5 ml diluted samples and separating them out in with the Hex
Rack (using the same binding conditions as the previous experiment). The wash procedure was
the same as that used for blood (see section 4.2.3) and DNA extraction done using the PrepGEM
kit (figure 4.5).
The same procedure was repeated with solid food samples as well (using General Mills
oat cereal as an example). The optimization to determine a workable dilution factor was the same
as with yogurt, but a different homogenization method was employed to prepare the solid food
sample. In this case, oat cereal were measured out and placed in a Magic Bullet blender with
TBS-Tween 20 with 5 mM calcium buffer and homogenized for 30 seconds (figure 4.5 a-b).
The resulting slurry was filtered into a 50 ml tube using a 100 pm cell strainer (BD falcon) to
remove large particulates, after which the E. coli was added (bacteria were kept away from the
homogenization blender to prevent contamination of negative control samples). It was found that
1 gm oat cereal to 48 ml buffer gave the best binding performance with the least sample dilution
and used this to characterize the sensitivity of the assay with 4.5 ml diluted samples in the Hex
Rack.
4.3 Results
4.3.1 Building a better magnetic rack
In my initial experiments with binding and separating bacteria out of blood with the
FcMBL beads (Chapter 2), I found that the 1 pm beads bound the smaller pathogens poorly but
the 128 nm beads that could effectively bind to bacteria (more than 90% capture of both E. coli
and S. aureus), but the bound bacteria proved difficult to extract out of blood with the DynaMag
2. Given that the bacteria could be separated out effectively in saline or plasma but not in blood,
it appeared that the problem was not poor binding but difficulty in pulling the smaller beads,
with their weaker induced dipole, out of blood. The magnetic force exerted on a bead depends on
the number of iron oxide nanocrystals embedded in it, which have a roughly uniform
concentration in the polymer matrix used to create the superparamagnetic beads we have
95
employed [142]. Consequently, the smaller volume of the bead volume, the lower the number
magnetic crystals in it and the weaker net magnetic force.
Examination of the DynaMag 2 rack and the magnets in the KingFisher Flex Magnetic
Particle Processor (employed for high throughput testing of the 1 Im FcMBL beads [124])
showed that these system had been poorly optimized for creating the high magnetic field
gradients required to pull out nanometer scale magnetic. The MACS column (Miltenyi Biotec)
could recover these beads, but the high surface area of the column made high levels of non
specific binding possible [79]. My work with the MFC showed that with the right setup, the
magnetic gradient from a standard rare earth magnet like those used in both commercial systems
could be greatly increased, so I developed a much more powerful magnetic rack to capture 128
nm beads and tagged bacteria out of blood.
Finite element modeling allowed me to reverse engineer the DynaMag 2 rack, evaluate its
weaknesses and screen a large number of different magnet shapes and configurations create a
better gradient. I found that over two millimeters of protective plastic separated the magnets of
the sample in the DynaMag 2 rack, which was a problematic since magnetic force drops
exponentially with distance from the magnets, so even a few hundred microns can make a large
difference The KingFisher has a similar problem; the protective plastic comb that sheathes the
magnetic head is much thicker than it needs to be (over Imm thick). The other primary weakness
of the DynaMag 2 rack was that the magnets are only on one side of the tube, so magnetic
particles on the far side of the tube are separated by the entire diameter of the tube (-10 mm). I
worked on correcting these two weaknesses in my design. I first focused on getting the magnets
as close as possible to the sample. The 5 ml FACS tube was selected for holding the sample
because it has the thinnest wall of any conventional test tube (800 pm) and, in all configurations
I examined, the magnets were placed in direct contact with the tube. To minimize the distance
between the magnetic particles in the sample and the magnets, I surrounded the tubes with
magnets rather than placing them one only one side, which led to the design of the Hex Rack
(figure 4.1 a-c).
The Hex Rack contains six magnets arranged in a hexagonal pattern around the tube.
Each is slightly offset so that the edge of the magnet is in contact with the tube, taking advantage
of the high gradient spike at the edge of the magnet which I found to cause bead pile up in the
early optical detection prototypes (Chapter 3). This created six equally spaced places around the
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perimeter of the 5 ml tube with the high magnetic gradients. Alternating the direction of the
magnetic poles into and out of the tube created an interlacing set of field lines in the sample
volume (figure 4.1 c). Forcing the fields to bend in this manner created large changes in their
magnitude and direction inside the tube, further increasing the field gradient.
Simulations showed that the Hex Rack produced a maximum magnetic field gradient
nearly three times that of the commercial DynaMag 2 rack system from Invitrogen, making it
much better suited for pulling out the smaller 128 nm beads that we work with for binding
bacteria out of blood (figure 4.1d). The average magnetic gradient in the tube volume was
boosted from 56 kg/Ams2 to 119 kg/Ams 2I boosting separation efficiency and decreasing bead
losses during washes in the PCR sample prep procedure despite the increased diameter of the 5
ml tube. The 5 ml volume of the tubes also made it possible to handle a much larger sample
volume than was previously possible, increasing the potential sensitivity our assay by allowing
me to process a larger sample with more pathogens. The Hex Rack greatly improved the
separation and retention of the 128 nm beads from blood; however, I developed an additional
simple method to further improve retention.
4.3.2 MEB and Improving Pathogen Separation
When the magnetic beads are magnetized by an applied magnetic field (like in a magnetic
rack), a magnetic dipole is induced in the bead, essentially turning the bead into a small magnet
itself. As this induced dipole is pulled towards the magnet in the rack, the beads will also be
attracted to other nearby beads in the samples [152]. The induced dipoles line up north to south,
forming into needle-like aggregates (figure 4.6 a-b). The magnetic force on the bead aggregate
increases linearly with the number of beads (assuming the magnetic beads area all the same size),
but the drag on the ellipsoid increases at a much lower rate [142]. The net result is that the
stochastic formation of these bead aggregates accelerates their separation out of the fluid. I
decided to add larger magnetic beads after the binding was completed to accelerate this
aggregation process of the 128 nm beads and create larger aggregates at the same time.
These larger magnetic enhancement beads (MEB) are added at the end of the binding
process and briefly mixed into the sample before magnetic separation. When the larger beads are
magnetized, they have a much larger magnetic dipole induced than smaller 128 nm beads, which
results in the smaller beads nearby being attracted to the MEB, accelerating the aggregation
process. The larger MEB beads play no role in the binding process themselves and were not
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functionalized with FcMBL; they merely had their surface blocked with biotin and BSA to
prevent non-specific adhesion.
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Figure 4.6 Magnetic Enhancement Beads
(a) Darkfield image showing 1 pm magnetic beads aggregating into needle like aggregates as
their induced magnetic dipoles attract each other when magnetized by an applied field (b)
Ellipsoid aggregates of 1 um magnetic beads in a microwell of the optical detection microdevice
(c) How the MEB work. The applied magnetic field induces a local dipole in all of the beads, but
the stronger dipole in the 1 um MEB bead attracts the smaller 128 nm FcMBL beads and tagged
fungi to it, forming a large aggregate quickly. The white arrow represents the induced magnetic
dipole (M) in the MEB. The induced magnetic dipoles in the 128 nm FcMBL beads is not shown,
nor is the local deformation of the applied B field caused by the beads aggregate.
There are three primary forces at work during the separation and washing process for the
sample preparation procedure that need to be considered to understand why the MEB are
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beneficial (figure 4.7 a). During separation, fluidic drag opposes the movement bead and tagged
pathogen movement towards the magnet and during the washing process the surface tension will
attempt to pull the beads down the tube away from the magnet during each fluid change. Neither
the KingFisher system nor the DynaMag 2 was capable of reliably removing 128 nm beads from
blood or holding them in place during wash steps. When I attempted to use the DynaMag rack,
the vast majority of beads and tagged pathogens were lost during the washing process, leading to
a very low detection rate with PCR.
A
b)
c)
I c2
Magnetic Force (Fag)
Figure 4.7MEB Theory
(a) Forces at work during separation and washes. Surface tension scales with the length of the
object in contact with the fluid, which is the circumference in the case of a spherical bead.
Images reprinted from [166, 167]. The drag force on an ellipsoid is higher than on a sphere in
low Reynolds flow, being roughly equivalent to the minor axis cross section [152], which would
be equivalent to the cross section of the MEB. Magnetic force scales with the number of
magnetic nanocrystals in the bead, which is proportional to the volume of the MEB because the
volume of the MEB is much larger than that of the 128 nm beads (b) Scaling analysis of the
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a) Sur Drag Force (FDrag)
Force Scaling Symbolic Local MFC/No lp/128
MC nm
a Circumference 27rR (RI/RO. 12 8 ) 7.8x
FDrag Area 7R2 (R1/RO.128)2 61x
Fuag Volume 4 (RI/R.)3 477x
- 7cR 3 0 1 28
MEB. This analysis assumes that the dimensions of the MEB dominate the behavior of the
composite aggregates since they are much larger than the FcMBL beads used for pathogen
binding (c) Illustration of how adding the 1 um MEB to 128 nm FcMBL beads (drawn to scale)
increases the size of the magnetic bead aggregate.
The fluidic drag on the ellipsoid aggregate scales approximately with cross section of the
MEB (-r 2) and the surface tension on the aggregates scales approximately with the
circumference of the MEB (-r). The main advantage of this method is that the magnetic force on
the aggregate scales with the volume (-r 3), so there is a net increase in the magnetic force when
the MEB are added that outweighs the increases in drag and surface tension (figure 4.7 b-c). For
a mixture of 128 nm FcMBL beads with 1 pm MEB, the net force on the beads should increase
by a factor of -8 during the magnetic separation (magnetic force increases by -477x and drag
increases by -6 1x) and by a factor of -61 during the washing process.
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Figure 4.8 Effectiveness of the MEB and Hex Rack
(a) Effect of adding different sizes and concentrations of MEB beads into diluted blood (1:4). All
samples were bound with the same concentration of 128 nm FcMBL beads (25 pg per ml
sample) but different amounts of biotin and BSA blocked MEB beads were added. Magnetic
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separation was performed on the KingFisher in an adaptation of the method developed by Super
et al. [124]. Adding the MEB significantly improved separation of E. coli out of blood (a=O. 05),
but no difference was observed between the two different MEB sizes tested or any of the three
MEB concentrations tested. n=3, error bar: SEM (b) Binding and Separation of Bacteria in
Blood with Hex Rack and MEB. Adding in the MEB and using the Hex Rack significantly
improved separation of E. coli out of diluted blood (1:1) relative to the DynaMag 2 rack
(a=0.05). It also showed an improvement when pathogen binding and separation (bacteria were
not bound with beads before being added to blood). No separation of E. coli bound in blood
were detectable with the DynaMag 2 while the Hex Rack and MEB showed 26% +13% binding
and separation. These results indicate that the sample treatments (1:4 dilution, glucose treatment
developed after my initial evaluations (Chapter 2) can boost the reliability of bacteria binding in
blood [124]. n- =3 error bar: SEM
Experimental measurements with the KingFisher system showed that this simple strategy
significantly improved separation after binding of bacteria in of diluted blood (a=0.05) and
decreased the variability of the process, boosting recovery of pathogens bound with 128 nm
FcMBL beads from 11% ±16% to 60% +2%. Varying the MEB size (1 Im or 2.7pm) and
concentration did not have any significant effect on the separation process (figure 4.8 a). Using
the Hex Rack together MEB significantly improved separation of magnetically tagged bacteria
out of diluted blood relative to the DynaMag 2 rack (a=0.05), boosting removal from 34% + 8%
to 85% + 3% (figure 4.8 b). No bacteria were recovered with the DynaMag 2 rack when I
attempted both binding and separation from diluted blood but the Hex Rack with MEB was able
to recover 34% + 8%. Using the new sample treatment conditions developed by other members
of the sepsis group since my initial evaluations (Chapter 2) boosted the reliability of binding in
blood as well [124]. These new conditions were used in the KingFisher MEB experiment,
yielding 60% ±2% of binding and separation of E. coli while the older sample treatment
conditions only yielded 26% ± 13% binding and separation in the Hex Rack. This treatment will
be used for subsequent binding and separation experiments. The following blood experiments
examined only separation of bacteria and not binding and were conducted with the dilution and
sample treatments outlined in Chapter 2 (1:1 dilution, cooling, heparin treatment). For
subsequent experiments, the Hex Rack with 1 pg of 1 pm MEB beads per 2 ig of 128 nm
FcMBL (1 jig MEB: 2 ig Bind) added after binding were employed to boost the separation and
minimize bead and pathogen losses during the washing process.
4.3.3 Results in Saline
101
The FcMBL beads are highly effective for binding and concentrating bacteria out of
saline for PCR analysis. The FcMBL and MEB beads themselves did not interfere with the DNA
extraction procedure at any concentration tested and showed no noticeable bacterial losses due to
binding, magnetic separation and two washes relative to the control with the Hex Rack and MEB
in saline (figure 4.9), evaluated with both PCR and qPCR. This was a major improvement over
initial experiments with the commercial magnetic rack, which was able to adequately separate
bacteria bound with 128 nm beads out of saline, but could not hold them in place against surface
tension during the washes. As a result, the majority of the beads and tagged pathogens were lost
after only two wash steps. Using the Hex Rack and MEB allowed me to virtually eliminate these
losses, at least in saline, and concentrate all the pathogens from up to 5 ml of fluid down into 80
I of water for DNA extraction and PCR.
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Figure 4.9: Effect of FcMBL beads and MEB on DNA extraction
Control samples had different concentrations of 128 nm FcMBL beads and I um MEB beads
added (in a ratio 1 pg MEB: 2 pg Binding beads) added to sample immediately before DNA
extraction. No significant difference in the DNA concentration (determined using qPCR analysis)
was found at any of the bead concentrations tested, indicating that neither the FcMBL beads nor
MEB had a major effect on the DNA extraction. For the binding and concentration curve, the
same amount of bacteria and beads were added to 1 ml of calcium buffer. The 128 FcMBL beads
were then allowed to bind, the MEB added, the magnetic particles separated out with a magnetic
rack and washed twice before being concentrated and resuspended for DNA extraction buffer.
No significant bacteria losses relative to the control were observed, indicating in saline all of the
E. coli in the sample and being bound and retained through the wash steps. n=3, error bar: SEM
4.3.4 Sample Preparation in Blood and Comparison to Commercial Kit
With these improvements in bacteria separation and retention, it was possible to begin
optimizing pathogen recovery out of diluted blood. These experiments were conducted using E.
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coli tagged with 128 nm beads before they were added to blood to examine only the sample
preparation procedure and not binding. Pathogen recovery at the end of the process was more
difficult to measure than binding, since the beads caused cell aggregation (making plating
inaccurate) and the inhibitors in blood made the qPCR suitable for comparing different methods
but not for absolute quantification with the saline genomic standard employed. Bead recovery
after the washing process in the Hex Rack with MEB was good (fig 4.8a), but in my preliminary
tests, there was an issue with human DNA being recovered along with the beads and bacteria
leading to non specific amplification. Repeating the tests in plasma showed virtually no non-
specific amplification, indicating that the primary cause of the non-specific amplification was
probably human DNA from phagocytes in the cellular fraction of blood.
Olysis IOO_ 31. 857 1.0
OlYsis loo 34. 85. 1.0
Clyis lo 38. 85. 1.0
OlYsis 50 39. 71. 26
Olysis 10 41. 57. 0.3
on+ 600 24. 100. 1.4
on- 41. 28.6 0.8
Table 4.2 Summary of qPCR for the three different sample preparation method.
Preparation defines which of the three sample methods tested were used and cfu/ml indicates the
E. coli concentration in each of the samples (2 ml of ]:] diluted blood for the Hybrid and
FcMBL methods, I ml of undiluted blood for the MolYsis method). Cq is the threshold cycle a
fluorescent qPCR signal was detected. Detection is the percentage of the samples run at each
concentration in which a signal was detected. STDEV is the standard deviation of the detected
cycle threshold values. Blood from seven different donors was tested with each method. Positive
and negative controls in saline (600,000 cfu/ml or 0 cfu/ml) were run with each assay to ensure
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the DNA extraction procedure was working. The 0 cfu/ml blood samples served as negative
controls for each sample preparation method.
Selecting a different primer that was less prone to attaching to human DNA greatly
reduced the non-specific amplification in the sample, making qPCR possible, but the remaining
human DNA still had an inhibitory effect on the amplification that reduced both the
amplification efficiency and the diagnostic sensitivity relative to the MolYsis sample preparation
method used for comparison. This reduced the reliability of the PCR amplification, so it could
detect pathogen concentrations down to 50 cfu/ml, but in only 43% of the samples (3/7) (table
4.2).
To get a better idea of how well FcMBL bead sample prep compared to the current state-
of-the-art systems for isolating bacterial DNA out of blood, I compared it to the MolYsis sample
prep kit (Molzym) (figure 4.10). This is one of the three kits commercially available for this
purpose and has been found to have the best sensitivity [21, 160]. The MolYsis kit relies on the
pathogens having tougher cell walls so that the human cells in blood can be selectively lysed and
their DNA enzymatically degraded without damaging the bacteria. Then the bacteria are pelleted
by centrifugation and resuspended in fresh buffer for DNA extraction. The multiple
centrifugation steps require a large amount of hands on time and the lysis is not completely
successful at solubilizing all of the debris from the human blood. Therefore, in addition to the
bacteria there is approximately 100 pl of gelatinous byproduct recovered from a 1 ml blood
sample after the final centrifugation, which requires 30 minutes of enzymatic degradation to
break down. This byproduct appears to have a large amount of hemoglobin which must be
removed during the DNA extraction process, so it requires proteinase K digestion and is not
compatible with the PrepGEM kit. The DNeasy solid phase extraction kit works well for this
purpose and was used for all samples in this comparison, including the FcMBL samples.
However, despite these difficulties, the MolYsis sample preparation method did work well for
isolating bacterial DNA from donor blood for qPCR. I found comparable sensitivity to that found
in the literature; at 50 cfu/ml the MolYsis kit could detect 71% of the positive samples and 85%
of the positives samples at higher bacterial loads [21, 160] (table 4.2). The FcMBL preparation
method had a higher number of false negative results, indicating either failure to recover the
bacteria or inhibition of the qPCR reaction.
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Figure 4.10 FcMBL vs. MolYsis Sample Preparation Methods, n 7, error bars: SEM
However, combining both the sample preparation methods to create a hybrid method
increased the reliability of using the FcMBL. In this hybrid method, the FcMBL beads were used
to concentrate the pathogens out of the blood so that the majority of the human cells could be
removed immediately and then the MolYsis kit was used to degrade any of the remaining human
DNA left in the sample. This eliminated the gelatinous blood debris and the human DNA, both
of which interfered with PCR. Amplification efficiency went up and the number of false
negatives went down (relative to the FcMBL method) using this method so that it was possible to
detect bacterial loads down to 100 cfu/ml with 99% confidence (p=0.0078125) [168]. However, I
cannot say that the Hybrid and MolYsis sample preparation methods are significantly different.
The Cq values with the Hybrid method are slightly lower than the MolYsis samples (indicating
slightly higher amplification efficiency), but the standard deviations for those Cq values are
higher than for the MolYsis samples (table 4.2). Applying additional statistics to the
experimental design, probit analysis and a larger sample size would be required to conclusively
establish the difference between the two [169].
Overall, the FcMBL sample preparation method was the least reliable of the three, with a
lower detection rate at all pathogen concentrations. However, the effectiveness of the hybrid
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version of the assay indicates that the bacteria are not being lost in the FcMBL sample
preparation method. Instead it appears that the excess of human DNA extracted from white blood
cells that phagocytose the beads is inhibiting amplification of the bacterial DNA causing a high
rate of false negatives. Using the MolYsis treatment to remove this DNA after FcMBL bead
separation prevents this inhibition and improves the reliability qPCR detection of the sample
preparation method.
The hybrid method was also more reliable for detecting bacteria in heavily anticoagulated
samples such as packed red blood cells from Blood Bank. These packed cells are treated with
citrate phosphate dextrose adenine (CPDA), which contains a cocktail of anticoagulants and
sugars [170], unlike the fresh donor samples used for the majority of the tests, which contained
only heparin. The hybrid assay, with its more extensive sample cleaning procedure, could
remove enough of these inhibitory molecules to make qPCR reliable for detecting E. coli spiked
into these samples. Consequently, combining the two methods creates a simple sample
preparation method that can both effectively remove human DNA and inhibitory substances from
blood, increasing PCR sensitivity and reliability.
4.3.5 Other Complex Samples
The medical industry is not the only group trying to rapidly detect rare pathogens in
complex samples. Detection of pathogenic bacteria in food currently uses techniques very similar
to the methods used to diagnose sepsis (culture and AST) and suffers from many of the same
limitations [32]. Every year in the United States, billions of dollars are spent screening food for
bacterial and fungal contamination and millions of contaminated products still reach store
shelves and cause millions of illnesses [171]. There are much fewer species of interest relative to
sepsis as well. Most companies are primarily focused on detecting E. coli 0157:H7, C. difficile,
Salmonella and Aspergillus, so there is a smaller number of pathogens for which the sample
preparation method must be tested [32, 35, 144, 172]. The primary limitation of current testing
methods is that they are slow, so food must either be stored during the testing process or
contaminated batches recalled after shipment, so there is great interest in a rapid diagnostic
method to detect contamination before the food leaves the factory. I have shown that the FcMBL
bead sample preparation method for PCR can rapidly detect bacteria in a few hours in blood. By
comparison, most foods are much simpler sample matrices to work with, so we suspected it
should be possible to adapt it to work with food.
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Figure 4.11 PCR detection of E. coli in different dilutions offood using FcMBL Sample Prep
(a) Testing different buffer dilution factors in plain, nonfat yogurt. The 1 gm yogurt: 9 ml buffer
was the only dilution factor tested that showed an specific PCR signal (assayed by gel
electrophoresis) significantly above the background in the 0 cfu sample (a=0.05).One milliliter
sample size, n =4, error bar: SEM (b) Testing different buffer dilution factors in oat cereal. The
1 gm cereal: 48 ml buffer was the only dilution factor tested that showed a specific PCR signal
above the background in the 0 cfu sample).Four and half milliliter sample, n=2, error bar: SEM
(c) Micorgraphs of homogenized oat cereal sample. Even at the 1:48 dilution factor, the
homogenized cereal sample was still quite complex, with a similar volume fraction of the fluid
('hematocrit') occupied by solid particulates as the diluted blood samples
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The main challenge with the switch to food was that it's much denser than blood, so
dilution and homogenization were first required to make the sample liquid enough for the
FcMBL beads to be able to circulate and bind bacteria. To determine the minimum sample
dilution required for yogurt, I began by adding different ratios of calcium buffer to yogurt (1 ml
buffer: 1 gram yogurt through 9 ml buffer: 1 gram yogurt), spiked in E. coli and determined if
the 128 nm FcMBL beads could then bind the bacteria. The binding and recovery was assayed
with qualitative PCR using E. coli specific primers because the large concentration of
Lactobacillus in the yogurt would make the plate-based depletion assay unreliable. The bound
pathogens were separated using the Hex Rack and MEB, and then washed before their DNA was
extracted and amplified using PCR. I found that the minimum dilution for getting reliable
binding and PCR detection was 1 gram yogurt: 9 ml buffer. None of the lower dilution factors
showed a PCR signal above the negative control for that dilution, indicating binding and
separation had failed (I had already established that trace amount of the yogurt did not inhibit the
PCR reaction, so it was much less likely that the PCR reaction itself was failing). (figure 4.11 a).
Diluting the sample with TBS-Tween 20 with 5 mM calcium ensured that there was enough
ionic calcium present for the CRD in the FcMBL protein to form a stable bond with the sugar.
A similar procedure was repeated to determine the workable dilution for oat cereal, with
the additional step that after the cereal was added to the buffer, it was homogenized for thirty
seconds in a blender and then run through a 100 pm filter (to remove particulates too large for
the pipettes handling fluid transfer to remove). The cereal itself soaked up a large amount of the
buffer, so I found that 1 gm cereal: 48 ml buffer was the minimum of the tested dilution (figure
4.11 b) in which the bacteria could be bound and detected with PCR. Even with this high of a
dilution factor, the solid content of the sample was similar to the diluted hematocrit blood (figure
4.11 c), so the beads were most likely unable to circulate effectively through the solid
particulates at lower dilution factors.
After a suitable dilution factor for pathogen binding and detection in the food samples
had been determined, a range of successively lower pathogens concentrations were recovered
and analyzed with PCR in 4.5 ml samples to determine the assay sensitivity. In yogurt,
concentrations as low as 22 cfu/gm of E. coli (100 bacteria total added to the 4.5 ml diluted
sample) could be bound, separated and detected with PCR (signal significantly above
background, a=0.05) (figure 4.12 a-b). The detection threshold in oat cereal was similar; I could
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reliably detect down to 100 cfu in the 4.5 ml diluted sample. However, because the oat cereal
was diluted much more for binding, this translated to a sensitivity of 1067 cfu/gm cereal (figure
4.12 c). Unlike blood, the FcMBL beads alone were able to wash and purify the pathogens
enough for PCR detection, without the need for a DNA degradation step, even in yogurt where a
large number of Lactobacillus would be recovered by the beads as well as the target E. coli. This
confirmed that the FcMBL beads could be employed to bind, separate and purify bacteria out of
multiple types of food for rapid PCR detection once the correct buffer dilution factor had been
found.
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Figure 4.12 : Bacteria Detection in Food using FcMBL Sample Prep Procedure
(a) Detection of E. coli in plain, nonfat yogurt (1gm: 9 ml dilution factor, I ml diluted sample
size). By using the FcMBL sample prep procedure, it was possible to concentrate the bacteria
sufficiently to detect as little as 100 cfu/gm above background (* indicates specific gel
electrophoresis signal significantly above 0 cfu/gm sample, a =0.05.) n=4, error bar: SEM (b)
Detection of E. coli in different types of yogurt (1gm: 9 ml dilution factor, 4.5 ml diluted sample
size). Detection in plain, nonfat yogurt, plain Greek-style yogurt and strawberry Greek-style
yogurt was compared. Increasing the sample size to 4.5 ml allowed me to boost the sensitivity in
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plain, non fat yogurt down to 22.2 cfu/gm (* indicates specific gel electrophoresis signal
significantly above 0 cfu/gm sample, a=0. 05). Detection in Greek-Style yogurt was not as good,
probably because this type of yogurt has a higher solid content than normal yogurt (part Qf the
liquid is strained out), so a higher dilution factor may be required for optimal binding in future
experiments. However, despite the increased protein and fruit content, the FcMBL beads were
still able to bind to the E. coli added to the samples and isolate them for PCR detection. n=4,
error bar: SEM (c) Detection of E. coli in oat cereal (lgm: 48 ml dilution factor, 4.5 ml diluted
sample size). By using the FcMBL sample prep procedure, it was possible to concentrate the
bacteria sufficiently to detect as little as 1067 cfu/gm above background (* indicates specific gel
electrophoresis signal significantly above 0 cfi/gm sample, a=0.05). Absolute number of
bacteria in the sample detected was similar in both yogurt and oat cereal, but the higher dilution
factor required for cereal meant the sensitivity in the undiluted sample was lower.
4.4 Discussion
By combining the FcMBL beads with improvements in magnetic separation for
nanometer scale beads, I have developed a simple sample preparation method to isolate bacteria
from complex samples such as blood or food for rapid PCR detection. The magnetic beads
provide a simple way to exert force on pathogens so that they can be concentrated them and have
PCR inhibitors removed at the same time, boosting the reliability of the PCR amplification.
The primary challenge for working with bacteria was that the smaller 128 nm FcMBL
beads that bind them effectively are difficult to pull out of complex samples such as blood. These
beads contain fewer magnetic nanocrystals, leading to a smaller magnetic force on the beads so
that they are more difficult to pull through viscous, colloidal solutions like blood or
homogenized food. The DynaMag 2 rack from Invitrogen could only separate out 34% t 8% of
the magnetically tagged E. coli from diluted blood, so a more effective method to recover the
pathogens needed to be developed. I created the Hex Rack and MEB to boost the net magnetic
force on the beads. The Hex Rack increased the strength of the magnetic gradient in the sample
tube both by minimizing the distance between the sample and the magnets and by taking
advantage of the gradient spikes at the edge of a rectangular magnet which caused problems with
uniform bead spread in the optical detection microdevice (Chapter 3). Finite element modeling
allowed me to evaluate several potential magnet geometries and pick the best one. This
configuration more than doubled the average magnetic gradient strength throughout the sample
volume and almost tripled the maximum gradient relative to the commercial rack.
The MEB acted as local magnetic flux concentrators in the sample fluid, drawing the
smaller 128 nm beads towards them and accelerating the aggregation process of the magnetic
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beads in the sample. This essentially gives the best features of both micron and nanometer scale
beads: the better binding of the 128 nm beads to bacteria and the superior magnetic separation
abilities of the larger 1 pm beads. Adding the magnetic enhancement beads made it possible to
use the 128 nm beads in the KingFisher system, which normally recovers only 11% ± 16% of the
bacteria from blood, but was able to bind and separate over 60% + 2% of E. coli spiked into the
blood with this simple addition. Surprisingly, the MEB concentration and size (1 pm or 2.7 pm)
did not seem to affect the separation. From the scaling theory, it was expected that the 2.7 Im
would be more effective than the 1 pm beads because ratio between the increase in magnetic
force over the increase in surface tension and drag was greater, but no difference between the
two was observed. The most likely explanation for this is that the same weight of 2.7 pm beads
actually has fewer beads than the same weight per ml 1 pm beads. Magnetic dipole interactions
drop off ~i/z 4 (where z is the distance between beads). Adding more the MEB beads was also
expected to boost the separation by reducing the average distance between the 128 beads and the
MEB, but the lowest concentration tested (1 pg MEB for every 5 pg of 128 FcMBL beads) was
still able to significantly improve separation in these experiments. This suggests that there are
additional factors at work during the aggregation process which are not accounted for in the
scaling estimates, such as the rate of aggregate formation, the average size of each aggregate and
its configuration (in terms of MEB and FcMBL beads) which merit further study to optimize and
understand the MEB phenomena. Overall the MEB greatly increased the reliability of the
separation and retention of the FcMBL bead and bound bacteria during the sample prep
procedure and they may prove useful for allowing many existing magnetic systems to work with
much smaller magnetic beads than is currently possible. The Hex Rack and MEB technology
both offer significant improvements on existing magnetic separation technologies. The Hex Rack
technology can be scaled up or down for a wide range of tube sizes or adapted to fit around
tubing for continuous separation applications. Together, they increase the separation speed and
the holding force on the beads and tagged pathogens during the washes required in the sample
preparation procedure.
Two different DNA extraction kits were employed during these experiments to detect
separated pathogens. The DNeasy Blood and Tissue kit (Qiagen) has been widely employed in
literature [160]. It utilizes proteinase K to digest the bacterial cell wall and then uses solid phase
extraction (SPE) on a silica column to bind the DNA, wash away contaminants and then elute
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purified DNA [173]. It is quite effective but also quite costly in terms of hands on time and has
several steps, making it more vulnerable to experimental error. The centrifugation steps make it
difficult to automate without an elaborate robotic system. The PrepGEM kit (Zygem) employs a
proprietary EAl enzyme that is able to digest the cell and any nucleases to release the DNA in a
closed tube assay. The digestions enzymes and buffer are added to the bacterial sample, and then
incubated in the thermocycler to break down the bacterial cells and release the DNA. A final
95*C incubation denatures the extraction enzymes so that they do not interfere with the PCR
reaction. This method takes the same amount of time as the SPE kit, but only has -5 minutes of
hands on time and is much easier to automate. Its main disadvantage is that the DNA is not as
pure because the contaminating proteins are enzymatically degraded but not removed from the
sample. Due to its simplicity, this method was employed for the majority of the tests except for
the comparison with the commercial MolYsis kit. Samples processed with the MolYsis kit
needed to be processed with proteinase K, so the DNeasy SPE kit was used for all three methods
(FcMBL, MolYsis, and Hybrid) to give a fair comparison. For all assays, extracted DNA was
eluted or released into 100 pl of liquid and 5 V1 of that solution was used for each qPCR reaction.
This means that the PCR reactions from the 100 cfu/ml (containing 100 bacteria total in the
starting sample), would have a maximum of 4-5 copies of the E. coli genome present. The 50
cfu/ml samples would contain 2-3 copies and the 10 cfu/ml samples would have between 0-1
genome copies. Therefore, the 50 cfu/ml samples are approaching the minimum copy number
that it should be possible to detect with PCR with the 1 ml blood samples employed in this
analysis. A larger sample size would be required to obtain enough genome copies to make
detection at lower concentrations consistent.
My initial experiments to develop the FcMBL sample preparation procedure were
evaluated with standard PCR and gel electrophoresis and compared to a 0 cfu/ml negative
control to give a qualitative readout. This allowed me to find the correct treatments to determine
an effective method to wash out the majority of PCR inhibitors in blood, check several E. coli
specific primers and select the one that had the least non-specific amplification when exposed to
human DNA from leukocytes, which would have given a large number of false positives in the
SYBR green qPCR used to analyze later samples. Several universal primer sets have been used
for attempting to detect bacteria out of blood using PCR, but these sets cannot differentiate
between different pathogen species. For these initial characterizations, I wanted something more
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specific and chose an E. coli specific target [29, 163]. This was particularly key for the yogurt
samples, where DNA from the harmless Lactobacillus in the sample would be amplified with a
universal primer set, regardless of the presence of E. coli in the sample. Cooling the blood
samples to 4*C minimized leukocyte phagocytosis of the magnetic beads but did not entirely
eliminate it, so the primary inhibitor remaining after the FcMBL procedure was human DNA
from leukocytes that ingested or bound the FcMBL beads. Once a suitable primer set and primer
concentration had been determined, there was minimal non specific amplification of human
DNA in the processed samples (verified with both melt curve analysis and gel electrophoresis).
Degrading this human DNA in the hybrid assay reduced this interference and increased the
sensitivity and reliability of the FcMBL beads. Conversion to Taqman primers or fluorescent
probes in the future would be prudent to minimize the risks from false positives due to non-
specific amplification further [174-176]. We also plan to switch from using an E. coli specific
primer in the near future to one of the universal 16s rDNA primers which amplifies a ribosomal
DNA sequence that is highly conserved in most bacteria, at least for blood samples [53, 177,
178]. The added advantage of this approach is that each bacterium contains multiple copies of
this sequence, making it easier to amplify than my current target (which has only one copy per
genome) [179]. Work is ongoing in the sepsis group to optimize the bead surface and FcMBL
properties to maximize pathogen binding and minimize non-specific adhesion or phagocytosis of
human cells to further improve the purity of the recovered bacteria.
The FcMBL sample preparation procedure was not as dependable for detecting bacteria
in blood as the MolYsis kit, primarily due to the presence of human DNA inhibiting the PCR
reaction for the FcMBL bead samples. The MolYsis kit enzymatically degraded the majority of
the human DNA in the sample, so it primarily suffered from contaminating proteins released by
the lysed blood cells (such as hemoglobin). However, combining these two procedures created a
hybrid sample preparation method increased the reliability of using the FcMBL beads. The pre-
concentration of the pathogens with FcMBL beads allowed the vast majority of the blood cells
and contaminating proteins to be removed before the lysis step and the MolYsis kit destroyed the
leukocytes separated with the beads and digested their DNA. The hybrid assay was able to detect
down to 50 cfu/ml (2-3 gene copies/pcr) in 71% of the samples tested, very close to theoretical
maximum sensitivity of the assay in its current form. So it appears the hybrid sample prep
method is not only recovering nearly all the magnetically tagged pathogens, but also cleaning
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their DNA sufficiently so that the PCR reaction can run at high efficiency. The hybrid method
was also the only one of the three methods that could effectively remove the anticoagulant
cocktail used to preserve packed red blood cells from the Blood Bank concentrates so that spiked
bacteria could be detected with qPCR.
All of these experiments to compare the three methods were conducted using 1 ml blood
samples due to limited availability of fresh blood for testing. I believe that the Hybrid method
would have an advantage at higher sample volumes (5 or 10 ml of blood). The amount of
contaminating proteins in the MolYsis samples would rise with the sample volume, but the DNA
contamination in the hybrid samples would be expected to stay constant, since the enzymatic
digestion process would largely eliminate it. Currently, the chaotropic lysis buffer used in the
MolYsis kit causes a large fraction of the bound bacteria to detach from the FcMBL beads, so
both magnetic and centrifugal separation methods must be employed in the hybrid method.
Further testing should let us find a lysis buffer which does not compromise the FcMBL binding
integrity so that the entire cleaning procedure can be done using magnetic separation alone. The
FcMBL beads offer an effective method to remove the majority of blood contaminants and
concentrate pathogens for PCR analysis, but more work to minimize bead phagocytosis and
degrade human DNA should increase the reliability of this method even further and make it
practical for use as a rapid PCR diagnostic for sepsis.
A simple adaptation of the FcMBL bead sample prep method also made it possible to
bind, separate and purify bacteria from food (both yogurt and oat cereal) for rapid PCR
detection. This demonstrates that these general opsonin beads have potential applications outside
of the medical field for rapidly detecting bacterial contamination in other complex samples.
Despite the yogurt samples containing a larger number of harmless lactobacillus bacteria, the
beads bound and recovered enough of the spiked E. coli to detect down 22 cfu/gm in yogurt (1
gene copy/PCR). The high dilution factor required to homogenize the oat cereal limited the
sensitivity to 1067 cfu/gm (5 gene copies/PCR) with a 4.5 m sample. Concentrating bacteria out
of larger sample volumes should boost the sensitivity further. It was much easier to obtain large
amounts of food for testing (relative to blood), so these characterizations were carried out with
4.5 ml of the diluted food homogenates. The foods tested also contained fewer PCR inhibitors
than blood, so sample preparation procedure was actually much more reliable in these samples
than it was in blood.
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Blood culture is currently the gold standard for sepsis diagnosis, but it is both slow and
inaccurate [28, 29]. PCR offers an amplification method sensitive enough to directly detect
pathogens and is believed by many clinicians to be the technology most likely to supplant blood
culture systems in the near future. An added advantage over blood culture is that PCR can detect
dead and damaged pathogens as well as viable ones, giving it a much larger sample population to
detect [52]. However, the presence of inhibitors in blood currently limits it utility [69]. I have
shown that the FcMBL magnetic beads offers a simple way to bind and hold pathogens from
blood or other complex samples and wash away the majority of PCR inhibitors present. When
combined with a method to remove contaminating human DNA from the bacteria, it forms a
robust sample preparation method that can detect clinically relevant pathogen concentrations
from blood with qPCR in less than four hours. These beads can bind and concentrate bacteria out
of diverse food types, offering a rapid method to test for pathogenic bacterial contamination.
Both PCR and AST testing methods are currently approved by the FDA for identifying bacteria
in food, but both analysis methods still require at least one to two days of culture to obtain
enough bacteria for identification [32, 34, 35]. During this time, the food must be stored at
considerable expense. The FcMBL sample prep method has the potential to speed this process up
so that contaminated food can be detected and destroyed before it leaves the processing plant
without significantly interrupting the workflow by requiring storage for multiple days.
The primary limitation of PCR is that there is currently no reliable method to assess the
antibiotic susceptibility of the detected pathogens in most cases. The sequence of resistance
genes for methicillin and vancomycin are known and can be used to detect Methicillin-resistant
Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), but the majority
of them mutate rapidly, making them difficult to assess with fixed PCR primers [180, 181].
FcMBL beads can isolate viable pathogens, so it is possible that part of the concentrated bacteria
can be set aside for subsequent testing if the PCR amplification identifies an infection.
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Chapter 5 Conclusions
5.1 Thesis Contributions
The goal of this thesis was to develop general magnetic opsonin beads and show their
potential applications for rapidly detecting sepsis, using both optical detection methods for
detecting fungi and PCR amplification for detecting bacteria. The accomplishments in each of
these areas are outlined below.
5.1.1 General Magnetic Opsonins
I have shown that the FcMBL beads can bind to a wide range of pathogens, including
fungi, gram positive and gram negative bacteria. Bead size, concentration and FcMBL density
was determined to give good binding to both bacteria and fungi in saline. Judging from
experimental measurements and collision theory, for effective capture, the magnetic opsonin
should be much smaller than the target pathogen (one tenth its radius or less). This minimizes the
relative velocity of the bead and pathogen during their initial contact so that the FcMBL can
establish binding avidity and allows a large number of the beads to attach to the surface of each
pathogen. Consequently, the 1 pm beads are more effective for binding to fungi (~5-10 pm in
diameter) while 128 nm beads are more effective for binding to bacteria (~ 1-2 pm) in diameter.
I also showed that there general magnetic opsonins could bind to bacteria and fungi in
blood, although additional sample treatments were required to improve the binding because
blood is a complex colloidal fluid. Diluting the blood 1:1 with saline increased the average
spacing between the red blood cells, reducing the hydrodynamic shielding effect and letting the
FcMBL beads circulate more effectively. Cooling the sample minimized the bead phagocytosis.
Bead concentrations, mixing times and separation times for pathogen binding were also
determined. With the correct treatment conditions, I was able to bind 86% of the fungi spiked
into diluted blood. Bacteria proved more difficult because the smaller beads were more difficult
to mechanically separate out of blood, which led me to design an improved separation system for
them in chapter 4.
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This is the first time that a single set of beads has been able to bind a diverse range of
pathogens in blood. Previous immunomagnetic separation systems have relied on antibodies or
lectins not compatible with blood [101-103]. I then go on to show that both fungi and bacteria
can be rapidly isolated and detected from blood using the FcMBL general magnetic opsonins.
Since these initial investigations, other members of the sepsis group have carried on these
experiments and found sample treatments and bead chemistries for blood that have boosted the
reproducibility and reliability of bacteria binding in blood [124].
5.1.2 Optical Detection of Fungi
I developed the Magnetic Flux Concentrator and microdevice to balance the magnetic
and convective forces on the FcMBL beads and magnetically tagged fungi. Capturing and
concentrating magnetically tagged pathogens is a relatively simple matter, but trying to optically
detect the captured pathogens is much more difficult because the large excess of magnetic beads
required for capture interferes with the analysis. Other groups have developed microfluidic
separation systems for isolating magnetically tagged cells from flowing fluid, but none of them
have been able to optically detect the captured cells in the same device [72, 78, 82, 84]. The
MFC and microdevice system allowed the fungi and excess beads to be concentrated out of
blood and spread into a thin layer. After fluorescent staining, the captured fungi could be
quantified by scanning over the microdevice with an epifluorescent microscope. Using this
method, I was able to detect 67% of the magnetically tagged fungi in a 5 ml blood sample in less
than three and a half hours and should be able to detect pathogen loads as low as 1 fungus/ml.
5.1.3 Rapid PCR Detection of Bacteria
Using the FcMBL beads, I developed a sample preparation method to rapidly concentrate
and purify pathogens out of complex samples for rapid PCR detection. To effectively isolate
bacteria tagged with nanometer scale magnetic beads, I developed a novel magnetic rack system
(the Hex Rack) that boosted the average and maximum magnetic gradients in the sample volume,
leading to more effective pathogen separation. I also developed the Magnetic Enhancement
Beads, which act as local magnetic flux concentrators inside of the sample to boost the
separation efficiency of the nanometer scale beads and their retention during multiple wash steps.
I showed that the combination of these two new separation technologies significantly improved
separation and retention of magnetically tagged bacteria out of blood over the commercial
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magnetic separation systems tested. These two technologies could have applications in a wide
range of magnetic separation applications.
Using these two new separation technologies, I developed a simple protocol to rapidly
separate bacteria out of complex samples such as blood or food matrices, concentrating the
bacteria and removing PCR inhibitors from the sample at the same time. This protocol could
rapidly separate the tagged pathogens out of blood and, when combined with an enzymatic
treatment to remove inhibitory human DNA, was able to detect down to 100 cfu/ml with 99%
confidence and down to 50 cfu/ml in the majority of samples. Performance of this Hybrid
method was comparable to the existing state of the art method (MolYsis).
By adding a sample homogenization step, the FcMBL sample preparation method could
also be readily adapted to bind, concentrate and purify bacteria out of different types of food
samples. This demonstrates that the general magnetic opsonins can not only bind a wide range of
pathogens, but also operate in wide range of different sample types. This is the first time that a
single sample preparation method for PCR detection has been shown to function in blood, dairy
and cereal samples.
5.2 Future Directions
Both the general opsonin magnetic beads and magneto-fluidic separation technologies
developed in this thesis have a wide range of potential future applications for concentrating and
detecting rare cells out of large, complex samples.
Despite the impressive results already obtained with the general magnetic opsonin beads,
work is ongoing at the Wyss Institute to optimize binding in blood and other complex samples.
New recombinant versions of MBL and other lectins are being studied to develop an opsonin that
can bind encapsulated bacteria (which neither wild type nor FcMBL can reliably bind) and other
pathogens resistant to MBL. Different bead surface coatings are under investigation to further
decrease the phagocytosis rate and perhaps dispense with the need to cool the sample. An in
depth investigation of the optimal bead concentrations, size combinations (to enable
simultaneous capture of bacteria and fungi) and sample additives is also underway. It has already
been found that adding 10 mM glucose reduces non-specific binding to the FcMBL beads [124].
This work should allow us to lower the bead concentration and binding time while still retaining
good pathogen binding in blood. The effect of different food components (simple and complex
carbohydrates, proteins, fats) will be systematically investigated to determine the complete range
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of sample types that the FcMBL beads can operate in and appropriate sample preparation
methods for each food type of interest. Improvements in binding will also increase the versatility
and reliability of the optical detection device and the sample preparation method for PCR.
For the optical detection microdevice, we will work on improving fluorescent pathogen
labeling, probably using FISH, to provide a more versatile confirmation of the calcofluor
staining in blood and determine species at the same time [28]. The system will then be automated
and combined with an inexpensive epifluorescent microscope developed at the Wyss Institute to
create a benchtop unit suitable for testing with clinical samples.
We will boost the sensitivity of the FcMBL bead sample preparation by combining
aspects of the optical detection micro device with the MEB technology so that magnetically
tagged bacteria from much larger blood and food sample volumes (up to 50 ml) can be
concentrated and purified for PCR detection. In blood, we can already detect down to 50 cfu/ml
in a one milliliter blood sample, so we should be able to boost this down to 1 cfu/ml by
increasing the sample size. We are currently establishing collaborations with several companies
in the food industry to develop a parallel project to detect bacterial and fungal contamination in a
range of different food types, including yogurt, cereal, cookie dough, milk, and fruit juice, using
PCR and optical detection methods.
In addition to improving pathogen separation, we will also improve the PCR reaction
chemistry. The current qPCR assay used for amplification is basic, so we will be collaborating
with experts in the PCR field to optimize the reaction conditions and prevent non-specific
amplification. The use of universal PCR primers and multiplex PCR detection will be
investigated to determine to create a diagnostic assay that can capture, concentrate, detect and
identify bacteria in septic blood samples. This system will then be tested with clinical samples
from local hospitals to show improved speed and reliability over blood culture diagnostics.
We also plan to continue investigating pathogen capture and detection with the FcMBL
beads in other samples, including sputum (upper respiratory infections), urine (urinary tract
infection), cerebrospinal fluid (meningitis) and platelet concentrates [33, 86, 131]. Platelet
concentrates have a very short shelf life, of which a large percentage is consumed waiting for
culture results to come back showing that they are safe for infusion [33, 86]. The FcMBL beads
have the potential to reduce this testing time to a few hours so that the concentrates can be tested
on the same day they will be used, greatly decreasing both storage costs and waste from
119
concentrates expiring during the testing process. The strategies for binding and separating
magnetic beads out of blood can also be applied assays using antibody based beads as well, so
the MFC microdevice, Hex rack and MEB may be of use in immunomagnetic separations to
rapidly isolate and detect circulating tumor cells, viruses and protein biomarkers from biological
samples.
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